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Abstract
Anti-epileptic medications (AEDs) are an important group of medications and their use
is increasing for treatment of not alone epilepsy but for their indications for mental
illness such as bipolar affective disorder and schizoaffective disorder. There has been
concern since the 1960s that these medications impacted on bone health and this was
initially studied in people with epilepsy. This study was carried out to examine the
totality of evidence from primary studies about fracture risk and falls risk in people
using AEDs, regardless of the indication for use. This study consists of a systematic
review of prospective cohort studies examining fracture and falls in adults using AEDs,
regardless of indication. Eleven studies were selected for inclusion, seven from the
United States, two from the Netherlands and one each from Finland and the United
Kingdom. The results of the included studies were analysed and assessed from the
standpoint of methodological quality. The studies were compared across their main
outcomes of interest; risk of fracture and risk of fall. It was found that there was an
increased risk of fracture with AED use and three of the five studies looking at falls
found the risk to be increased. Initial and repeat prescriptions for AED treatment (with
its risks of side effects) require the same attention to the four principles of bioethics as
all medical care should receive. This process should be structured, aided and, if
necessary informed, by regulatory and legal percept which have been developed over
years of interaction between the legal system and complex healthcare matters.
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Chapter 1: Introduction
1.1 Context
I am a psychiatrist by profession, and treat illnesses including schizophrenia, bipolar
affective disorder, schizoaffective disorder and recurrent depressive and anxiety
disorders. I have also worked in the learning disability services where many of my
patients had epilepsy and attended neurology clinics to try to achieve optimum seizure
control. I also attended a joint clinic run by the neurology physician, in collaboration
with the learning disability service physician and psychiatrist.
When I went to the neurology clinic I observed the doctors prescribing “bone
protection” for the patients who were on long term anti-epileptic drug treatment, e.g.
sodium valproate. I was surprised as patients could be treated with the same
medication, sodium valproate, for mood stabilisation, and I had not seen this practice
in mental health clinics I have attended. This piqued my interest in this area of study.
1.2 Purpose
I want to look at whether the use of anticonvulsant medication, which can be used for
seizure control, mood stabilisation and headache, predicts fracture or falls. I want to
look at this relationship regardless of the reason for using the medication. I will do this
by carrying out a systematic review and meta-analysis of the available literature as this
type of study design serves to examine the totality of evidence with respect to the
impact of an exposure (medication use) on outcomes of interest (fracture or falls). I
want to look specifically at cohort studies where the exposure is identified prior to
identifying the outcome. For this reason, they are associated with less risk of bias than
case-control and cross sectional studies. These types of study designs will be
considered in greater detail in the methods section (Chapter 2) of the thesis. I will then
synthesize the information available from suitable studies as this will allow me to
answer the question:
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“Do anti-epileptic drugs, regardless of the treatment indication, predict an increased
risk in the incidence of falls and fractures?”
To ensure clarity of the research question, the population (P), exposure (E) and
outcome (O) have been clearly defined as follows:
Population – adults over 18 years of age
Exposure – anti-epileptic medication
Outcome – Falls and/or fracture.
Secondly I want to look at the ethical issues around prescribing medications with
potentially serious long term side effects, insidious as the progression of same may be.
I want to examine this issue with reference to when such treatments are initially
instituted when a patient is very unwell, and their judgement impaired.
Thirdly I want to look at the regulatory advice for doctors who find themselves in the
role of “repeat prescriber” of these kinds of medications over many years, particularly
given that this job very often falls to the junior medical staff.
Lastly I want to make a recommendation, following thorough study, regarding whether
local or national policy/guidelines should be instituted in this regard.
1.3 Background
1.3.1. Epilepsy
1.3.1.1. What is epilepsy?
In simple terms, epilepsy is the tendency to have seizures. However, a more precise
definition of epilepsy has been developed in recent years by experts in the field of
neurology. The International League Against Epilepsy (ILAE) produced an official report
in 2014 following recommendations of a task force (1). This changed the previous
working definition that had been in use since 2005. This had regarded someone as
having epilepsy if they had experienced two unprovoked seizures more than 24 hours
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apart (1). The revised definition states that the patient should be diagnosed with
epilepsy, a disease of the brain, if they meet any of the following conditions:
“(i) At least two unprovoked (or reﬂex) seizures occurring more than 24 hours apart;
(ii) one unprovoked (or reﬂex) seizure and a probability of further seizures similar to
the general recurrence risk (at least 60%) after two unprovoked seizures, occurring
over the next 10 years;
(iii) diagnosis of an epilepsy syndrome (1).”
The ILAE, founded in 1909, has more than 100 national chapters, including one in
Ireland. Each national chapter has elected officers and members who are doctors and
other health care professionals interested in epilepsy (2). They have formal links with
the World Health Organisation for the Global Campaign Against Epilepsy (2). Their
stated aims are “to advance and disseminate knowledge about epilepsy, to promote
research, education and training, and to improve services and care for patients,
especially by prevention, diagnosis and treatment” (2). Whereas previously epilepsy
was considered a “disorder” or a “condition”, the ILAE and the International Bureau for
Epilepsy have agreed it should be considered a disease (1). It was felt this better
reflected the serious nature of epilepsy.
A seizure occurs when a large number of the cells send out an electrical charge at the
same time (3). This abnormal and intense wave of electricity overwhelms the brain and
results in a seizure, which can cause muscle spasms, a loss of consciousness, strange
behaviour, changes in emotions and changes in body functions, such as blood pressure
and heart rate (4). Because the abnormal electrical activity can arise in any part of the
brain a seizure can affect any of the functions we know the brain has. Seizures vary in
frequency, with some people having less than one per year and others experiencing
several per day (3). They also vary considerably in duration, from very brief absences
to prolonged convulsions (3).
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1.3.1.2What causes epilepsy?
The cause of epilepsy is regarded as multifactorial, that is, a number of factors may be
at play, interacting to increase the risk. It is thought that between 10 and 30% of cases
of epilepsy are due to genetic illness (3). Furthermore, any illness or disease process
that affects the grey matter in the brain can cause epilepsy (3). For example, between
5 and 10% of newly diagnosed epilepsy is caused by brain tumours. The most common
acquired causes of epilepsy are vascular, post infection or post trauma (3). In around
30% of cases no cause is identified (3).
1.3.1.3 Prevalence of epilepsy
The prevalence of a disease is defined as the number of cases of a disease existing in a
given population (5). According to the World Health Organisation approximately 50
million people currently live with epilepsy worldwide with an estimated prevalence of
between 4 and 10 cases per 1000 population (6). This number is higher in lower
income countries, at between 7 and 14 cases per 1000 people. In 2009 a study was
commissioned by ‘Brainwave The Irish Epilepsy Association’ to examine the prevalence
of epilepsy in Ireland. This was conducted by the University College Dublin Centre for
Disability Studies and the study was published in Epilepsia, the official journal of the
ILAE (7). This study used self-report data, ant-epileptic drug prescription data, primary
care data, specialist care data and inpatient data in Ireland (7). The findings showed a
national lifetime prevalence of self-reported epilepsy among adults of 10 per 1,000
population. They also found that there was a national prevalence of treated epilepsy in
Ireland of 8.3 per 1,000 (2002) rising to 9 per 1,000 (2005) for those over the age of 5
years (7).
Incidence is the rate of new (or newly diagnosed) cases of the disease. It is generally
reported as the number of new cases occurring within a period of time, usually
reported per year (5). The Irish study quoted above did not report any data on
incidence of epilepsy in Ireland (7). However, the World Health Organisation report
that annually between 30 and 50 per 100 000 people in the general population are
diagnosed with epilepsy (6).
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1.3.1.4Morbidity and mortality associated with epilepsy
Seizures cause physical and emotional distress, missed days at work and school and
limitations on some activities, such as driving and swimming (3). Along with the
morbidity associated with seizures, there is also a risk of sudden death (3). This is
called Sudden Death in Epilepsy (SUDEP). It is defined as "sudden unexpected,
witnessed or unwitnessed, non-traumatic and non-drowning death in an individual
with epilepsy, with or without evidence of a seizure and excluding documented status
epilepticus where post-mortem examination does not reveal a cause for death" (8).
There are approximately 130 epilepsy related deaths every year in Ireland with
epilepsy being one of the top ten causes of death in young people (early or premature
deaths) (9). There is a higher risk of SUDEP in poorly controlled epilepsy.
1.3.1.5 Prognosis with epilepsy
Around 60% of the people who are diagnosed with epilepsy stop having seizures within
five of years of being diagnosed, following the introduction of anti-epilepsy treatment
(3). In 20% of people diagnosed with epilepsy they have periods of remission and
periods of relapse (3). For a further 20% of people diagnosed with epilepsy remission is
never achieved (3). Risk factors for poorer prognosis include diagnosis of intellectual
disability, multiple seizure types and having clusters of seizures (3).
1.3.1.6 Treatment for epilepsy
The mainstay of treatment is with anti-epileptic medication, or anti-epileptic drugs
(commonly, and hereafter in this thesis, referred to as AEDs). A balance must be
sought between the benefits and drawbacks of treatment. Approximately 70% of
people stop having seizures at some point after introducing treatment (3). These types
of antiepileptic medication do not stop a seizure once it has started and they are not
viewed as cures for epilepsy, nor are they cures for the cause of epilepsy (3). The goal
of treatment is to try to prevent a seizure occurring.
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The medications used to treat epilepsy vary in the way they act on the brain and their
side effect profiles. Examples of medications used include Acetazolamide,
Carbamazepine, Clobazam, Clonazepam, Ethosuximide, Felbamate, Gabapentin,
Lamotrigine, Levetiracetam, Lorazepam, Phenobarbital, Phenytoin, Pregabalin,
Oxcarbazepine, Rufinamide, Tiagabine, Topiramate, Valproate, Vigabatrin,
Zonisamidde (3). Some of these medications are benzodiazepine medications,
clobazam, lorazepam, clonazepam.
As stated above there are a number of mechanisms of action of the AEDs. Gamma-
aminobutyric acid (GABA) is an inhibitory neurotransmitter; that is, it blocks
transmission between nerve cells in the brain. Some of the AEDs work by increasing
the activity of GABA including clonazepam, clobazam, phenobarbital, and tigabine (3).
Sodium valproate is thought to work by increasing the activity of GABA but also affects
potassium and sodium conduction (3). Nerve cells are excitable cells and sodium
channels play a role in transmission of action potentials. Some of the AEDs act on
neuronal sodium channels: carbamazepine, lamotrigine, phenytoin (3). Other
medications act on calcium channels, glutamate (an excitatory neurotransmitter) and
enzyme activity (3). The exact mechanism of action of all of the AEDs is not fully
understood (3).
The issue of when epilepsy is deemed inactive or to have resolved was also the subject
of the ILAE report in 2014. The report identified that “Epilepsy is considered to be
resolved for individuals who either had an age dependent epilepsy syndrome but are
now past the applicable age or who have remained seizure-free for the last 10 years
and off anti-seizure medicines for at least the last 5 years” (1). “Resolved” is not
necessarily identical to the conventional view of “remission or “cure” but it was hoped
that formulating a view on this issue would reduce the burden and stigma of having
epilepsy (1, 10).
In addition to treatment to try to prevent seizures some patients are prescribed
‘rescue medication’ which is designed to be used to try to stop a seizure that has
already started. The National Institute for Health and Care Excellence (NICE) provides
national guidance regarding health and social care in England. NICE is a non-
departmental public body established under primary legislation and based in London
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(10). Its summaries and guidance are often referenced by doctors in other countries,
including Ireland. Regarding rescue treatment for epilepsy their guidance is as follows:
“Only prescribe buccal midazolam or rectal diazepam for use in the community for
children, young people and adults who have had a previous episode of prolonged or
serial convulsive seizures”(11).
If epilepsy is not responsive to medication after five years of treatment, during which
time a number of medications are trialled, epilepsy surgery may be considered (3). This
can take the form of lobectomy, or vagal nerve stimulator placement (3). These
surgeries are designed to remove the part of the brain causing the seizures (e.g. in the
case of lobectomy for tumour or hippocampal sclerosis) or palliation of severe
intractable epilepsy (in the case of vagal nerve stimulator) (3).
1.3.2 Bipolar affective disorder and Schizoaffective Disorder
1.3.2.1What is bipolar affective disorder?
The World Health Organisation’s Tenth Edition of the International Classification of
Diseases (12) is one of two diagnostic manuals used in Ireland. It uses the following
definition for bipolar affective disorder. “Bipolar affective disorder is a disorder
characterized by two or more episodes in which the patient's mood and activity levels
are significantly disturbed, this disturbance consisting on some occasions of an
elevation of mood and increased energy and activity (hypomania or mania) and on
others of a lowering of mood and decreased energy and activity (depression)” (12).
Some manic episodes and some depressive episodes are accompanied by psychotic
symptoms (12). However, people with bipolar affective disorder do not experience
psychosis when their mood is stable (12).
Usually recovery is achieved between these episodes, the duration of which may vary
(12). For example, an episode of mania may have an abrupt onset, with a median
duration of four months (12). An episode of depression can last longer with a median
length of six months (12). Bipolar affective disorder can present any time from
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childhood to old age though the mean age of onset in community studies is at
seventeen years of age (13).
1.3.2.2 Prevalence of bipolar affective disorder
The lifetime risk for bipolar affective disorder lies between 0.3 and 1.5% (13). The Irish
mental health charity ‘Aware’ state on their website that “40,000 Irish people suffer
with bipolar affective disorder” (14). However, they do not cite the origin of this
statistic. A review looking at articles that examined prevalence data in Europe found
that the majority of studies reported 12-month estimates of between 0.5-1.1%. The
cumulative lifetime incidence was reviewed from two prospective-longitudinal studies
was found to be between 1.5 and 2%. There was a higher lifetime incidence calculated
from the studies when bipolar II disorder was included at 6% (15).
The incidence of bipolar affective disorder is reported much less often as compared to
the prevalence rate due to the wide variation in data, with published studies reporting
an incidence rate ranging from 2.6 to 20.0 per 100 000 per year (16).
1.3.2.3 Definition of schizoaffective disorder
As stated above, the World Health Organisation’s Tenth Edition of the International
Classification of Diseases (ICD 10) is one of two diagnostic manuals used in Ireland (12).
Regarding schizoaffective disorder, the ICD 10 uses the following definition: “A
disorder in which the individual suffers from both symptoms that qualify as
schizophrenia and symptoms that qualify as a mood disorder (e.g.k depression or
bipolar disorder) for a substantial portion (but not all) of the active period of the
illness; for the remainder of the active period of the illness, the individual suffers from
delusions or hallucinations in the absence of prominent mood symptoms” (12). When
the ICD 10 refers to symptoms that qualify as schizophrenia it means symptoms of
psychosis in this instance.
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1.3.2.4 Prevalence of schizoaffective disorder
The prevalence of schizoaffective disorder was estimated by Perälä et al in 2007 at
0.32% of the population in Finland (17). A French review by Azorin et al estimated the
prevalence at 0.5 to 0.8% (18). An earlier Irish study cites the lifetime prevalence at
between 0.2 and 1.1% (19). There are limited data available regarding the incidence of
schizoaffective disorder and this is likely to be due to issues regarding diagnostic
stability. That is, patients may become unwell and receive a diagnosis, e.g. of
depression, then later during the period of that illness develop psychosis and receive a
diagnosis of schizoaffective disorder (14).
1.3.2.5 Prognosis in bipolar affective disorder and schizoaffective disorder
Bipolar affective disorder and schizoaffective disorder is associated with high levels of
morbidity due to episodes of illness, and also mortality. The rate of completed suicide
in these groups is approximately 10% (20). Some patients do not respond to the initial
treatment and require trials of alternative medication or to take a number of different
medications together. There is evidence for poorer overall physical health in these
patient groups, with higher mortality from physical health problems than in the
general population (21). Hoang et al compared mortality ratios in a cohort with
psychiatric illness and a cohort from the general population following general hospital
admission. The study demonstrated that the mortality gap widened over time, and for
bipolar disorder, the ratio was 1.9 (1.6 to 2.2) (21). Ratios were higher for unnatural
than for natural causes but three quarters of all deaths were certified as natural.
Increases in ratios for natural causes, especially circulatory disease and respiratory
diseases, were the main components of the increase in all-cause mortality (21).
1.3.2.6 Treatments for bipolar affective disorder and schizoaffective disorder
The treatment for mental illness, including bipolar and schizoaffective disorder, takes
the form of medication and psychotherapy and also social support. Psychotherapy is
less studied in bipolar affective disorder than in depression that occurs alone (called
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unipolar depression) but psychoeducation regarding relapse prevention has been
shown to reduce the rate of relapse (13). Some psychotherapy options have been
studied in psychosis also including cognitive behaviour therapy for persistent
hallucinations or delusions and cognitive remediation (13).
The mainstay of treatment for bipolar affective disorder is pharmacological treatment
with a mood stabiliser medication (13). The medications used for this are lithium,
sodium valproate, carbamazepine and lamotrigine. Sometimes newer antipsychotic
medications are also used with the purpose of stabilising mood (13). However there
have been concerns around the long term safety of this approach due to fears
regarding development off metabolic syndrome, resulting in higher risk of diabetes,
obesity and elevated cholesterol (22). In schizoaffective disorder antipsychotic
medications are often used to control the psychotic symptoms of the illness. Even
when this is the case mood stabiliser medication is usually required to treat the mood
disorder component (13). The mood stabilisers used are the same as the ones used in
bipolar affective disorder.
Three of the mood stabiliser medications are also used as anticonvulsant medication.
These are sodium valproate, carbamazepine and lamotrigine (13).
1.3.3 Prescribing of anti-epileptic medication:
The group of medications referred to in the epilepsy section are called anticonvulsant
or antiepileptic medications. This is correct terminology. However, it is also correct to
refer to the three medications mentioned in the above paragraph, used in mood
disorders, as mood stabilisers. For the purpose of this thesis I will refer to the group of
medications as antiepileptic medication. This term, and its abbreviation ‘AED’, was the
most oft used in the literature I reviewed. However, this is not intended to infer the
indication for use. The uses, as outlined above, include epilepsy, bipolar affective
disorder, and schizoaffective disorder. However, this group of medications is also used
to treat chronic pain, nerve pain and headache (23).
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In the report carried out by the UCD School of Disability Studies, anti-epilepsy drug
data were used to help to calculate the prevalence of epilepsy (7). However, the figure
was adjusted to reflect the possibility that the drug was being used for another
indication. The original data were not included in the study (7). The prevalence data
calculated from the figures they used was for treated epilepsy, therefore the
prevalence data from this section of the study reflects the prevalence of prescribing of
any one of 15 anti-epileptic medications, once adjustments were made. This showed a
prevalence of prescribing, post adjustment, of 8.3 per 1,000 people in Ireland in 2002
to 9.0 per 1,000 people in 2005 (7).
1.3.3.1 Prevalence of prescribing of anticonvulsant/anti-epileptic medication
It is helpful then to get an idea of how many people are prescribed these medications,
regardless of their indications. In 2014, De Groot at al published their review of AED
prescribing calculated from national drug databases in Spain, Denmark, Germany, and
two each from the Netherlands and the United Kingdom (24). The prevalence of
prescribing of any AED varied from 88 per 10,000 persons (The Netherlands) to 144 per
10,000 in Spain and Denmark in 2001 (24). In all of the databases reviewed, prevalence
of prescribing increased year on year during the period of assessment from 2001 to
2010. The increase seen was between 6% in Denmark and 15% in Spain (24). The
authors felt that this increase over time was unlikely to reflect an increase in the
diagnosis of epilepsy and more likely to reflect the increasing number of newer AEDs,
many of whom have indications for use other than epilepsy. This was deemed to be
the case as in a recent meta-analysis prevalence of long term epilepsy in developed
countries was found to be 5.8 with a figure of 4.9 for active epilepsy (25).
1.3.4 Bone mineral density, osteoporosis and fractures
Bones make up the human skeleton and have been referred to as our scaffolding. Bone
has a complex array of functions and sometimes problems can arise, such as
osteopenia, osteoporosis and fractures.
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1.3.4.1 Bone
Bone is made of crystals of mineral bound to protein (26). This gives the bone strength
and resilience so that the skeleton can absorb impact without breaking (26). These
minerals and collagen comprise two types of bone material; compact bone and spongy
bone. Compact bone is the outer portion of each bone which looks like a solid mass;
cancellous (spongy) bone refers to a network of columns called trabeculae whose aim
is to reduce stress and pressure on the bone (26). The outer layer of cancellous bone is
composed of compact bone. Bones without an interior mass of cancellous bone have a
medullary cavity instead (26). The shaft of the long bones (such as the humerus of the
arm or the femur of the thigh) are hollow (27). This space is filled with adipose tissue
and/or red marrow, which forms blood cells (27). The medullary cavity is lined with
endosteum, a thin layer of connective tissue. At birth, the marrow of all bones created
blood cells. In adulthood, blood cells are only produced in the bones of the skull,
thoracic cage, spinal column, pelvic and shoulder girdles, and heads of the humerus
and femur (27). The hip joint is where the femur inserts into the pelvis in a ball and
socket joint.
1.3.4.2 Our changing bones
The mineral part of the bone contains calcium and phosphorus and this is bound to
collagen (26). Bone reaches its peak density in humans in our early twenties but
remodelling continues throughout life. Bones are modelled and remodelled, or
changed, in response to many stimuli. These include the physical stress on the bone,
damage to the bone, or need for minerals stored in bone that arise elsewhere in the
body (26).
One of the things bone architecture responds to is mechanical force, or lack thereof.
Therefore, bones reduce in density when someone does not bear weight on them- an
extreme example of this occurs in space when the astronauts are in a weightless
environment for an extended period of time (26). The outer cortical bone of a person’s
dominant arm is seen to be denser in response to greater demand or stress placed
upon it (26).
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Phosphorous and calcium are necessary for other parts of the body to function and
survive, including nerves and muscle, such as the heart (26).  We need the right
amount of calcium in our cells for them to work adequately (26). Bone must be
responsive to changes in mechanical loading or weight bearing, both of which require
strong bones that have ample supplies of calcium and phosphorus, as outlined above
(26). Also, when calcium and phosphorus are scarce, regulating hormones take them
out of the bone and divert them to where they are needed. If too much is removed
from the bone, it can become weak and at risk of fracture (26). Osteoblasts are the
cells that lay down new bone. Osteoclasts are the cells responsible for breaking down
bone by dissolving it, which is called resorption (26).
The systems that govern this remodelling of bone are dependent on signalling. This
signalling is largely conducted by a system of hormones that aims to keep the levels of
calcium in our cells at an optimum level. The main hormones involved are calcium
regulating hormones: parathyroid hormone, calcitriol (active vitamin D) and calcitonin;
sex hormones: oestrogen and testosterone; and other systemic hormones: growth
hormone (Insulin-Like Growth Factor), thyroid hormone and cortisol (sometimes
referred to as the “stress hormone”) (26).
Parathyroid hormone (PTH) is produced by the four parathyroid glands, which are
located near the thyroid gland, in a person’s neck. The PTH acts on both bone and
kidney, telling these organs how much calcium they should hold on to. If the body’s
level of calcium is low the parathyroid gland with generate more PTH (26). PTH also
manages how much calcium a person absorbs from their gastrointestinal tract, by
stimulation of the active hormone generated from vitamin D (calcitriol), which acts on
the intestines. Too much PTH can result in bone loss (26). Calcitonin promotes the
action of osteoblasts in generating bone and inhibits the action of osteoclasts in
breaking down bone.
The sex hormones are also important in maintaining bone. Oestrogen acts on both
osteoclasts and osteoblasts to stop bone breakdown throughout life. The marked
decrease in oestrogen at menopause is associated with rapid bone loss (26). The high
levels of sex hormones at puberty have a role in growth and strengthening of long
bones (25). Testosterone stimulates muscle which promotes bone growth.
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Testosterone is also converted to oestrogen and this has the same effects on bone in
men as it does in women (26). This is one of the reasons why age and gender are
important factors in risk of fractures and why many of the studies included later
control for these. Sex hormones can get disrupted in severe weight loss, such as
anorexia nervosa, and this can increase the risk of osteoporosis.
Growth hormone is produced by the pituitary gland and promotes skeletal bone
growth. Thyroid hormones control the energy and activity level of cells in the body
including those in bone (26). Cortisol is necessary for normal bone development, but in
larger quantities it can inhibit bone growth (26). Synthetic forms of cortisol, called
glucocorticoids, are used to treat many diseases such as asthma and arthritis. They can
cause bone loss due both to decreased bone formation and to increased bone
breakdown, both of which lead to a high risk of fracture (28). For this reason, these
drugs are referred to in many of the studies referred to later in the thesis.
1.3.4.3 Problems for our bones: Focus on Osteoporosis
Deficiencies in calcium, vitamin D and phosphorus can result in reduced bone strength.
Genetic disorders and hormonal disorders involving the hormones described above
can also result in bone ill-health.
Osteoporosis is defined as “a skeletal disorder characterized by compromised bone
strength, predisposing to an increased risk of fracture” (29). Bone strength refers not
just to the amount of bone present, also called density, but also to the quality thereof
(29). Therefore, in osteoporosis, bones become gradually weaker. Sometimes young
people have reduced bone strength due to genetic disorders or because of poor
nutrition (e.g. low calcium and vitamin D levels) and lifestyle (e.g. little/no weight
bearing activity). However, most fractures of bone in young people are due to
significant force of the injury (26). Then, later in life, bone loss begins due to bone
breakdown, which picks up speed after menopause in women (26). In general, bone
formation decreases with age in men and women, and bone resorption continues.
Therefore, an imbalance between bone resorption and bone formation results in loss
of bone mass, leading to fragile bones (26). An osteoporotic fracture is “a fracture that
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occurs with very little trauma or force and from a standing position, that is usually not
great enough to cause broken bones, usually indicating that the bone is weak” (30).
Sometimes osteoporosis is only detected when someone suffers a fracture from a non-
traumatic event. Osteopenia is the early stage of Osteoporosis and once someone has
osteopenia they are at high risk of developing Osteoporosis (30). Osteoporosis and
osteopenia are diagnosed using a bone density scan of the spine and hips called a Dual
Energy X-ray Absorptiometry (DXA /DEXA) scan (30). It is used to measure the density
(thickness) of bones which is used as a proxy to estimate the strength of the bone.
1.3.4.4 Prevalence of osteoporosis and osteoporotic fractures
Johnell and Kanis carried out a systematic review and meta-analysis of fractures which
was published in Osteoporosis International in 2006 (31). They concluded that, in the
year 2000, there were an estimated 9.0 million osteoporotic fractures of which 1.6
million were at the hip, 1.7 million at the forearm and 1.4 million were clinical
vertebral fractures (31). They found that the greatest number of osteoporotic fractures
occurred in Europe (34.8%) (31). They also found that, world-wide, osteoporotic
fractures accounted for 0.83% of the global burden of non-communicable disease, and
for 1.75% of the global burden of non-communicable disease in Europe (31). The
National Institute of Health in the United State estimates that 10 million people there
have osteoporosis (26). In Europe, it is estimated that 30% of people aged 65 years and
over fall each year and that approximately 10% of these result in fractures and that
20% require medical care (32).
The rates of fracture for the total population of Ireland were assessed by a population
based study published in 2009 in Osteoporosis International. The authors reported the
rates of fracture, in those aged 50 years and over, were 407 and 140 per 100,000 for
females and males, respectively (33). They also projected this would increase by 100%
by the year 2026, assuming stable incidence rate (33).
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1.4 What do we know about the link between medications for epilepsy and
bipolar affective disorder and bone health?
For many decades, clinicians and researchers have been concerned about a link
between AEDs and bone health (34, 35). Many of the early studies focussed only on
people with severe epilepsy and very often these studies were carried out on people in
institutions. This was without consideration of possible confounding factors such as
lack of weight-bearing activity, poor nutritional intake or medical ill-health (36).
Epilepsy itself has been shown to deliver an increased risk of fracture, about double
that of people without epilepsy (37). Therefore, methodologically sound, longitudinal
studies were required to try to clarify the extent to which seizures and injuries
therefrom, side effects from medication and other issues were contributing. There
then ensued a number of studies showing individuals treated with liver enzyme
inducing AEDs had lower bone mineral density than those treated with non-liver
enzyme inducing AEDs, which were latterly synthesised into a meta-analysis published
by Fraser et al in 2015 (38). This study looked only at people treated with AEDs due to
epilepsy. The mechanism of action for this effect relates to increased metabolism of
vitamin D in the liver as a result of the liver enzyme inducing medication which then
has a knock-on effect on PTH (39).
In addition to studies about LEI versus non-LEI AEDs there followed a number of
studies showing both types of AEDs were associated with increased risk, though many
of these were retrospective studies or case-control studies (40, 41). Shen et al,2014,
published a systematic review of studies looking at individuals treated with all types of
and demonstrated an increased risk of fracture associated with AEDs (42). While this
paper examined the risk of fractures in detail it did not review the risk of falls
associated with AEDs. Also the evidence included in this systematic review included
retrospective studies and case control studies. Of note the Shen paper synthesised
evidence relating to use of AEDs regardless of whether the participants had a diagnosis
of seizure disorder.
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1.5 Where is the gap?
There is no research I have identified which examines the totality of evidence with
respect to the impact of an exposure (AED medication use) on the outcomes of
interest (fracture or falls).
There are national guidelines in other countries (including the NHS in the UK) regarding
the use of these medications in treatment of epilepsy (43). These give
recommendations about advice for patients and prescription of bone protection. The
National Institute for Clinical Excellence (NICE) clinical guideline for management of
epilepsy recommends monitoring vitamin D levels and other measures of bone health
and bone metabolism, including serum calcium and alkaline phosphatase every 2-5
years for all patients taking enzyme inducing drugs (43). The same set of guidelines for
management of bipolar affective disorder do not mention the risk of bone loss or
fracture, nor do they make any recommendations regarding prevention of same (44).
Therefore, this review of the totality of evidence available pertaining to all users of
these medications is important. The results of the review have important ethical and
legal implications which will be considered in the discussion section of the thesis.
1.6 Dissertation outline
Chapter 2 of the thesis will outline the methodology used for the systematic review of
cohort studies included therein. The exact nature of both systematic review and a
cohort study will be explained in detail. The standardised guidelines adhered to and
the reasons for same will also be explained. The strategy used to identify all relevant
studies will be outlined and the methods whereby relevant studies were selected will
be explained. The MeSH terms used will be included in this chapter. Methods of
assessment of methodological quality of the studies will also be made clear.
Chapter 3 will identify how the studies were selected initially, including a flow chart
demonstrating same. There will be a description of each of the studies relating to AED
use and fractures only. There will be a description of each of the studies relating to
AED use and falls only and there will then follow a description of the studies that
29
looked AED use and both falls and fractures. A table will represent the main findings of
each study. The impact on fracture risk, falls risk and the confounders included in the
study will be discussed, as well as the population studied.
Chapter 4 will include a discussion of the findings of the studies included in the
systematic review. The ethical issues relating to prescribing medications with
potentially serious long term side effects will be reviewed. The discussion will be
structured using the four principles of biomedical ethics: autonomy, beneficence, non-
maleficence and justice.
The legal implications of the results for clinicians and patients will be discussed. The
author will examine in particular the role of “repeat prescriber” of medications, noting
that this job very often falls to junior medical staff. Here the focus will be on Duty of
Care of Healthcare Professionals.
Chapter 5 will comprise a summary of the key components in the thesis. The potential
policy implications of the results of the review will be outlined in the context of the
ethical and legal implications outlined in the previous chapter. The strengths and
weaknesses thereof will be highlighted and areas for further research suggested.
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Chapter 2: Methodology
2.1 Introduction
The overall aim of this chapter is to detail the methods used for this systematic review
of cohort studies. The rationale for completing a systematic review is discussed along
with a justification for including studies with a cohort design only. The search strategy
will detail the efforts made to identify all relevant studies that focus on exposure to
anti-epileptic medication (AEDs) and on the occurrence of falls and fractures as the
outcome. The inclusion and exclusion criteria for study selection and data extraction
will be described followed by a description of the how the methodological quality of
the studies was assessed. The purpose of this section is to enhance the transparency
and reproducibility of the methods, in accordance with the relevant standardised
reporting guidelines.
2.2 Study Design
The study consists of a systematic review of cohort studies. There may be many studies
conducted all over the world looking at similar issues and a systematic review is a
method of combining that knowledge and information in a thorough and appropriate
way, making it more useful for clinicians. A review is a re-examination of findings but
its remits are not clearly defined. A review is a systematic review when it uses a
consistent approach to identify all potentially relevant studies that address a particular
research question. The research question itself must be clearly formulated; i.e. it must
relate to a specific population, the exposure must be clearly identified, and the
outcome of interest must be clearly stated. The kind of study design best suited to the
research question must be examined. In the case of this study the outcome of interest
is fractures and falls. As this is an adverse outcome that can take some time to occur,
large observational studies are the most suited to capture this event.
This systematic review was conducted in accordance with the Meta-analysis of
Observational Studies in Epidemiology guidelines (MOOSE) (45). The reason for doing
so is to ensure the research was conducted and reported in a standardised fashion.
31
Stroup et al proposed this system of reported systematic reviews and meta-analyses. A
steering committee of 27 members studied practice at that time in systematic reviews
and generated a checklist for future practice. Their work was funded by the Centre for
Disease Control and Prevention in the United States. Their paper states: “use of the
checklist should improve the usefulness of meta-analyses for authors, reviewers,
editors, readers, and decision makers”. The over-arching goal is to allow informed
timely clinical decisions be made using a synthesis of the research available This is
possible due to improved transparency and reproducibility of reviews of cohort studies
(45).
2.3 Cohort Study
A cohort study is one of a number of observational studies. This means that
participants are exposed to something (e.g. medication or risk factor) and observed for
an outcome (e.g. adverse event or disease) as they are followed up over time. An
exposed population is usually compared to an unexposed population to allow
calculation of the risk of the outcome occurring.  The exposure is not assigned by the
researcher, as in a randomised trial, but observed as having happened due to
prescribed treatment in the case of AED use as the exposure. At the end of a period of
time, the number of times the outcome occurred in each group is calculated. These
figures are then compared with one another. Cohort studies have higher external
validity than randomised controlled trials, and therefore the research is deemed to be
more applicable to the general population.
Some the outcomes of interest in cohort studies can take a long time to develop, e.g.
disease, and so the duration of follow up is often lengthy. This gives rise to risks of bias
if a large number of the population have been lost to follow up. It is imperative to the
quality of the study that the researchers are cognisant of the risk of bias, including the
contribution of confounders. This is assessed for when looking at the quality of the
studies included and will be further discussed in the quality assessment paragraph of
this chapter. A confounder is an exposure that is not the exposure of interest. It is
associated with the outcome of interest, and could potentially cause/prevent same.
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Therefore, a false association could be assumed to arise from the exposure of interest
if this exposure is not assessed managed within the study. With respect to the
outcome of interest in this systematic review, the potential confounders are the
known causes and risk factors in the development of osteoporosis and fractures. As
there are many of these, some of the studies will have selected different confounders
for which they will control. The summary table of the included studies will list the
confounders used by each study.
The question to be addressed by this thesis is “Do anti-epileptic drugs, regardless of
the treatment indication, predict an increased risk in the incidence of falls and
fractures?” This is best answered by cohort studies as they are at reduced risk of bias
as compared to case control and cross sectional studies. Only prospective cohort
studies will be included. In a prospective cohort study the exposure is identified and
measured and the population is then followed up, thereby further reducing the risk of
bias.
2.4 Search Strategy
The systematic review aimed to identify ass studies that examined the impact of using
AEDs on incidence of falls and fractures. Screening of Pubmed, ISI Web of Science, the
Cochrane Library, EMBASE and PSYCHInfo was completed for the period June 1967 to
June 2016. This was carried out in March 2016. In June 2016 the saved searches were
reviewed for emergence of any new relevant studies. No restrictions were applied with
respect to age, gender, or language. The search terms were “anticonvulsants”,
“carbamazepine”, valproic acid”, phenobarbitone”, “phenytoin”, “lamotrigine”,
“topiramate”, “gabapentin”, “leviteracetam”, and “fracture”, “fall”, “bone density”,
“osteoporosis” and “osteopenia”. To identify as many articles as possible the
PSYCHInfo database was included to try to reflect psychiatric use of AEDs also. The list
of search terms can be viewed in appendix 1. The search was supplemented by hand-
searching references of retrieved articles and searching Google Scholar. The databases
were searched using both free text and MeSH terms to reflect the most recent
additions to their libraries. In EMBASE the ‘explosion’ feature was used to optimise the
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results obtained. The search was reviewed by a research librarian in Royal College of
Surgeons, Dublin.
2.5 Study Selection and Data Extraction
Studies were included if they were prospective cohort studies or randomised
controlled trials that looked at the relationship between AED use and fractures and
falls. They comprised original data from epidemiological studies. The exposure of
interest was treatment with AEDs, regardless of the reason. There were two outcomes
of interest; fractures and falls. Studies were included if risk estimates were provided
with adjustments for potential confounders.
The author read the titles and/or abstracts of the identified references and eliminated
irrelevant studies. Studies that were considered eligible for inclusion were read fully in
duplicate and their suitability for inclusion was determined by the author. The
supervisor acted as a second independent reviewer in cases where there was
uncertainty around inclusion/exclusion of studies. Disagreements were managed by
consensus.
The studies were examined and all essential information was extracted using a
standardised form. The following data were collected from each study: author, year,
country of research team, study design, population, sex, age, follow-up year, outcome
and exposure definition, effect estimates with 95% confidence intervals and variables
adjusted for. Appendix 2 contains a template of the data extraction form.
2.6 Quality Assessment
The quality of the studies was assessed by using the Newcastle-Ottawa Scale (NOS)
criteria. The Newcastle-Ottawa scale was developed during collaboration between the
Universities of Newcastle, Australia and Ottawa, Canada. It was developed to assess
the quality of nonrandomised studies. A 'star system' has been developed in which a
study is judged on three broad perspectives: the selection of the study groups; the
comparability of the groups; and the ascertainment of either the exposure or outcome
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of interest for case-control or cohort studies respectively (46). For cohort studies the
NOS criteria were: (i) representativeness of the exposed cohort; (ii) selection of the
non-exposed cohort; (iii) ascertainment of exposure; (iv) demonstration that the
outcome of interest was not present at the start of the study; (v) adjustments and
matching; (vi) assessment of outcome; (vii) long term follow up and (viii) response
rate. Each item was scored from 0 to 1 except (v) which has a maximum score of 2. The
studies scoring higher than 7 were deemed to be high quality studies. Studies scoring
between 4 and 6 on the scale were assessed as being of ‘moderate quality’, and 0-3 as
being of ‘poor quality’.
2.7 Narrative synthesis
In Chapter 3 the results of each included study will be summarised. The results will be
described in terms of the outcome measures used in each study. Studies may describe
the risk of the outcome of interest occurring using absolute risk, relative risk, odds
ratio and hazard ratio.
Absolute risk (AR) is the rate of occurrence of an event in a group, e.g. 10% of the
people who were exposed to the risk factor got the illness. Relative risk (RR) is the size
of effect of an intervention of interest relative to the size of effect of a comparison
intervention (which might be no intervention/exposure). If 10% of the unexposed
cohort have the outcome and 5% of the exposed cohort have the outcome, then the
RR is 10/5 = 2.
Odds ratio (OR) expresses the odds of having an event compared with not having an
event in two different groups (likely to be an exposed and unexposed group).
Therefore, in the example used above the risk in the exposed group is 10/90 and the
risk in the unexposed group is 5/95. Then the OR is calculated as follows:
(10/90)/(5/95) = 2.11. The adjusted odds ratio (AOR) is the OR adjusted for
confounders, as stated in each individual paper. An AOR >1 demonstrates increased
risk of fracture or fall in those exposed to AEDs. An AOR of <1 would demonstrate that
the exposure is protective with regard the outcome (47). This is a better estimate of
the true effect of the exposure on the outcome in most instances.
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The hazard ratio (HR) in a study is also called the weighted risk ratio and this looks at
risk but takes into account survival to that point in the study, i.e. it takes account of
time (3). It is an estimate of risk at any given time and is a ratio of the estimate of risk
in one arm of the study as compared with the estimate in the other arm, at that time.
Both odds ratios and risk ratios are cumulative risk ratios whereas hazard ratios are not
(47).
As the outcome of interest in this research question is dichotomous – i.e. fall/no fall or
fracture/no fracture, the relative risk or odds ratio can be pooled if there are sufficient
good quality studies using these measures. Confidence intervals (CI) of 95% are used to
estimate how precise the number shown in the risk ratio is. The studies, regardless of
how large, are not reflecting absolutely everyone everywhere. Therefore, confidence
intervals are used to tell us that there is a 95% chance that the true population value
lies between the two numbers reported (47).
2.8 Summary
This chapter described the method used to identify and select relevant studies for the
systematic review. The nature of the studies we will be encountering have been
described and the statistical terms we will encounter in the results chapter of the
thesis have also been explained. The next chapter will describe the results of this
systematic review.
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Chapter 3: Results
3.1 Introduction
This chapter will identify and describe the studies included in detail. A flow diagram
will show how the results from the original search were refined to those included in
the discussion below. The summary points regarding the populations studied will be
outlined. A table will be used to show clearly the main points in each study. There will
follow a narrative synthesis, reviewing the findings of each study. This will include a
brief description of the study, the exposure and outcome definitions, the potential
confounders included and the results. There will be an assessment of the quality of
each study and a synthesis of the relevant findings.
3.2 Study identification
The original search string in Pubmed yielded 1750 results, and the search in the
Cochrane Library yielded 179 results. There were 1059 results from the Web of Science
search and 7925 results from the Embase search. PsychInfo database resulted in 104
results. This gave a total of 11019 results. When duplicates were removed there were
9720 results. These articles were screened by title and abstract and 127 full text
articles were reviewed. Of the full text articles reviewed, a total of 11 were deemed
eligible for inclusion. These were read fully by the author and by the supervisor and
their suitability for inclusion confirmed. Of these, three were concerned only with falls,
six only with fractures and two studies had both fractures and falls as two primary
endpoints.
The most common reason for excluding articles was that they were not prospective
cohort studies. Some of those excluded pertained to children. Some of the articles had
falls and fractures as primary outcomes but only looked at benzodiazepine or Z
hypnotic medication as exposures.
Figure 3.1 illustrates the flow of articles included in this systematic review.
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Figure 3.1- Flow Diagram of articles included in systematic review
3.3 Description of the Studies
Eleven prospective cohort studies appropriate to this systematic review were selected;
Tromp et al, 1998 (48), Bohannon et al 1999 (49), Ensrud et al 2002 (50), Ensrud et al
2003 (51), Merrill et al 2005 (52), Carbone et al 2010 (53), Mezuk et al 2010 (54),
Nicholas et al 2013 (55), Nurminen et al 2013 (56), Ham et al 2014 (57), Velez et al
2014 (58).
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The studies selected included people from all over the world using AEDs for a variety of
reasons. Of the studies with fracture as the primary outcome four studied populations
in the United States of America (49, 51, 54, 58). There was one study each from the
United Kingdom (55) and Finland (56). Two of the studies with falls as the primary
outcome were from the United States (50, 52), with the third based on a population in
the Netherlands (57). There were two studies with both falls and fractures as primary
outcomes, one each from the United States (53) and the Netherlands (48). Sample
sizes in the studies ranged from 51 (52) to 194,734 (58).
The included studies focused on diverse population groups. The recruitment for the
studies on fractures only is set out first. Bohannon et al recruited 2590 women from
the Duke Established Populations for Epidemiologic Studies of the Elderly (EPESE)
focussing on five counties in North Carolina, USA (49).  Ensrud et al examined a cohort
of 8127 women recruited for the Study of Osteoporotic Fractures, from population-
based listings in Maryland, Minnesota, Oregon and Pennsylvania, USA (51).  Mezuk et
al recruited 67,387 (mainly male) patients receiving care through the Veteran’s Health
Administration, USA (54). Nicholas et al sourced a cohort of 63,259 men and women in
their study from the General Practice Research Database in the UK (55). Nurminen et al
used data 1283 men and women who participated in a longitudinal population based
study carried out in Lieto, Finland (56). Velez et al studied 194734 people registered
with a large administrative claims database PharMetrics Database, USA (58).
Ensrud et al studied 6,301 participants from the same cohort described in their
fracture study above, recruited for the Study of Osteoporotic Fractures, from
population-based listings in Maryland, Minnesota, Oregon and Pennsylvania, USA, for
their study concerning falls and AEDs (50). Merrill et al examined a cohort of 51
inpatients in the Buffalo Psychiatric Inpatient Centre, New York, USA (52). Ham et al
studied 2,407 participants from the B-PROOF study (B vitamins for the prevention of
osteoporotic fractures) in which the participants were from three Dutch cities (57).
Tromp et al studied a cohort of 1449 men and women from the Longitudinal Aging
Study in Amsterdam for their paper concerning predictors of falls and fractures (48).
This studied people in three regions of the Netherlands over a period of 10 years.
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Carbone et al, in looking at falls and fractures, examined 138,667 participants from the
Women’s Health Initiative, a long term national health study in the United States (53).
Regarding age and gender profile, there was also evidence of some diversity across the
studies. Three of the six studies relating to fractures and AED were concerned with a
cohort aged 65 and older (49, 51, 56). Two of these studies state explicitly that these
were “community dwelling” (49, 51). The third study (56) states that one in 20 of the
population included resided in institutions. The remaining studies pertaining to
fractures included one population aged 50 and older (54) and two populations with a
mean age of 47.6 years (58) and 42.2 years (55) respectively. Of these six studies two
were concerned with women only (49, 51) and one with a population that was 97%
male (54).
Of the studies looking at AED use and falls, two were concerned with a community
dwelling cohort aged over 65 years (50, 57). The third was concerned with psychiatry
inpatients with a mean age of 59 years (52). One of these studies (50) was based on an
all-female population. Of the studies looking at both falls and fractures in AED users
one looked at women only between the ages of 50 and 79 years (mean age 63 years)
(53). The second examined a population described as “community dwelling” who were
65 and older (48). One of these two studied an all-female population (6). Table 3.1
displays the descriptive characteristics of the included studies.
3.4 Key findings of the Studies
3.4.1 Narrative Synthesis of the Included Studies
3.4.1.1 Studies concerned with risk of fracture only
Bohannon et al in the United States, 1999, set out to determine if sociodemographic,
lifestyle, health and drug use factors were associated with a higher risk of incident
non-vertebral fracture. 2,590 women were recruited through the Duke Established
Populations for Epidemiologic Studies of the Elderly (EPESE) focussing on five counties
in North Carolina. This all female population included African American women are
described as community dwelling, and they were followed up for six years. The
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baseline assessment was an in person interview, conducted in participants’ homes. It
included information regarding demographics, physical functioning, presence of
selected health conditions, current medication, use of health services and social
support. This was in order to ascertain independent variables of interest known to be
associated with increased fracture risk. Participants were also assessed for depression
and cognitive impairment. There was a second in person interview after three years.
Telephone interviews were conducted annually for the six years of follow up.
Regarding exposures of interest, medication use was recorded for the following:
diuretics, phenytoin, prednisolone, thyroid supplements, calcium supplements and
oestrogen. Of these, one is an anti-epileptic medication; phenytoin. This study
included the medications above, regardless of indication for use. The primary outcome
of interest was incident non-vertebral fracture. This outcome was defined as “a
fracture involving the hip, arm wrist, or other site, excluding the back or spine”. The
mechanism of ascertaining whether the primary outcome had occurred was via self-
report of a fracture during one of these interviews. Secondary outcomes were all
incident non-hip, non-vertebral fractures; and subsequent fractures reported during
follow up interviews (49). Potential confounders included in the Bohannon study were
age, race, education, income, residence, lifestyle (including alcohol and smoking),
medications (as outlined above) and condition of health.
In the results, regarding the exposure of interest, the authors did not report how many
of the participants were taking phenytoin. Phenytoin was given a weighted mean value
of 0.015 among the white participants and 0.006 among the black participants. The
results showed that phenytoin use was associated with an increased risk of all
fractures (odds ratio 3.06, CI 95% 1.11-8.48). When phenytoin use and non-hip, non-
vertebral fractures were examined there was also an increased risk (OR 3.74, CI 1.42-
9.84). Bohannon et al also found that phenytoin led to increased risk of a subsequent
fracture (OR 3.09, CI 0.87-10.97) (49) but in the case of this finding there was a wide
confidence interval which crossed the value of one. Therefore, this second finding
regarding phenytoin is not significant.
Ensrud et al, 2003 also conducted their study in the United States. They set out to see
if Central Nervous System (CNS) active medications increased the risk of fractures in
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8,127 community dwelling older women. The authors noted that black women were
excluded from the study due to their lower rate of fracture. This was a cohort recruited
for the Study of Osteoporotic Fractures, from population-based listings in Maryland,
Minnesota, Oregon and Pennsylvania, USA and they were followed up for an average
of 4.8 years. The initial recruitment for the Study of Osteoporotic Fractures was in
1986-1988 (9,704 women) and baseline examination took place at this time. In 1992
the survivors from that original cohort were invited to have a fourth examination
which included a questionnaire and 8,127 did so by 1994. These women were then
contacted by postcard or telephone every four months to ask whether they had
experienced any incident non-spine fractures until 1999.
The CNS active medication the participants were taking is the exposure in the study.
This was ascertained in interview at a clinic visit. The participants had a clinic visit or a
home visit (or a telephone interview if neither of the above were possible) to ascertain
the medication they were taking.  All containers of prescription and non-prescription
medication were reviewed by the interviewer in the face to face interviews. The
authors generated a list of four classes of CNS active medications: benzodiazepines,
antidepressants, anticonvulsants and narcotics. The indication for prescription of the
AED was not assessed.
The outcome of interest was “all non-spine fractures”. This was defined as all non-
traumatic, non-vertebral fractures and, as stated above, was reported during quarterly
telephone or postal contact. All fractures were confirmed by radiographic reports; hip
fractures were confirmed by reviewing pre-operative x rays. Fractures occurring
because of major trauma were excluded.
Potential confounders included in the Ensrud study were age, self-reported health
status, oestrogen use, lifestyle (including activity level and smoking), previous dizziness
and falls, cognitive impairment, weight change, bone mineral density, speed when
walking and ability to rise from a chair.
Of the 8127 participants, 123 (or 2%) were taking one AED, 65 were taking phenytoin,
34 were taking phenobarbital, 27 were taking carbamazepine and 12 were taking
another AED which was not specified. The authors found that after the results were
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adjusted for age, women taking AEDs were at increased risk for any fracture (HR 1.68,
95% CI 1.16-2.43). They were also found to be at increased risk for hip fracture
specifically (HR 2.00, 95% CI 0.94-4.25). This hazard ratio was reduced when the
statistics were also adjusted for bone mineral density (HR 1.38, 95% CI 0.88-2.18 for
any non-spine fracture and HR 1.51, 95% CI 0.56 to 4.08). When the hazard ratios were
adjusted for multiple potential confounders the HR was reduced further still
(multivariate HR 1.25; 95% CI 0.79 – 1.98 for any non-spine fracture and multivariate
HR 1.37; CI 0.51-3.73). It was noted by the authors that while the HRs were still greater
than 1.0, the confidence intervals were wide.
The authors also obtained adjusted risk estimates for each fracture outcome. They
state that they did this by adding covariates individually and simultaneously to models
that included current use and age as predictors. The result using this method showed a
higher risk of any non-spine fracture in someone using an AED (age adjusted RR 1.68;
95% CI 1.16-2.43, multivariate RR 1.25; 95% CI 0.79-1.98). The calculated relative risk
of hip fracture (age adjusted) was RR 2.00; 95% CI 0.94-4.25). The calculated relative
risk of hip fracture (multivariate) was RR 1.37; 95% CI 0.51-3.73). The authors state
that excluding women with epilepsy did not alter these results (51).
Mezuk et al, United States 2010, sought to assess fracture risk in people aged 50 and
older, with serious mental illness, treated with AEDs. People with bipolar affective
disorder were identified from those receiving care through the Veteran’s Health
Administration, USA from the VA National Psychosis Registry. The cohort consisted of
67,387 people, of whom 97% were men. There were no racial exclusions. There was no
information regarding accommodation. The cohort consisted of 29,029 people with
bipolar affective disorder and 38,358 without a diagnosis of serious mental illness but
in similar age demographic, also recruited from the Veterans Health Administration
database. The participants were followed up for 4.5 years.
Exposure of interest was prescription of AED, which was identified from pharmacy
records through the Veteran’s Administration prescription benefits manager group.
The authors included liver enzyme inducing medications phenytoin, fosphenytoin,
mephenytoin, phenobarbital, carbamazepine, primidone, oxcarbazepine and
topiramate. They also included non-enzyme inducers divalproex, lamotrigine,
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gabapentin, tigabine, and levetiracetam. The exposure was recorded if any of the
agents were used before the date of data They included data regarding duration of
AED use and when it was last used. The outcome of interest was “all fractures”. The
authors stated they chose to include traumatic fractures also. The data regarding
occurrence of a fracture was obtained from coding for diagnoses in both inpatient and
outpatient administrative records. While all fractures were recorded, there was a
separate analysis of hip fractures. Potential confounders included in the Mezuk study
were age, gender, race, region, income, depression and alcohol or substance misuse.
The results showed that 65% of the sub-group with bipolar disorder used AEDs,
compared with 2% of the group without bipolar disorder. Of the people prescribed
AEDs, 45.7% were taking divalproex (sodium valproate in Europe), 25.9% were taking
gabapentin, 9.5% were taking carbamazepine, 7.7% were taking lamotrigine and 5.2%
were taking topiramate. Having ever used an AED resulted in an increased risk of all
fractures over the study period for the whole study population (HR 2.42; 95% CI 2.23-
2.63). There was also an increased risk for hip fractures specifically (HR 2.35; 95% CI
1.86-2.99). The study also noted that patients with bipolar disorder had an increased
risk of fracture independent of AED use (HR 1.21, 95% CI 1.10-1.33, Wald x2 = 14.8, p =
0.0001).  The authors stated that the relationships between bipolar disorder and AED
use and fracture were similar for men and women but they did not show this data. The
authors also examined the relationship between enzyme inducing AEDs and any
fracture and showed the risk to be higher than that with non-enzyme inducers (HR
2.19, 95% CI 1.97 – 2.43, and HR 1.66; 95% CI 1.54 – 1.79 respectively). The authors
state that excluding people with epilepsy from the analysis did not alter the results
(54).
Nicholas et al in the United Kingdom compared fracture risk in people using liver
enzyme inducing medication with people using non liver enzyme inducing medication.
The cohort was people with active epilepsy and was sourced from the General Practice
Research Database in the United Kingdom. There were 63,259 participants and the
median duration of follow up was 2.93 years. Individuals were included in the cohort if
they had a received a diagnosis of epilepsy and received a prescription for an AED. 49%
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of the cohort were women and the mean age of the participants was 42.2 years. The
participants’ type of residence was not recorded.
Exposure of interest in this study was AED treatment, and the information regarding
this was also obtained from the General Practice Research Database (GPRD).
Participants were classified as being treated with (i) AED treatment including one or
more liver enzyme inducer (LEI)or (ii) AED treatment including only non-liver enzyme
inducing (non-LEI) AEDs. Everyone in this study had epilepsy, therefore the indication
for use of AED must be deemed to be for epilepsy. The primary outcome of interest in
this study was diagnosis of fracture recorded in the GPRD. The secondary outcome of
interest was hip fracture. Possible confounding variables included were alcohol use,
previous use of AEDs, previous seizures, falls or fractures, health condition and
medication use.
The results showed that 9,754 men were prescribed non LEI AEDs and 16,508 were
prescribed LEI AEDs. Of the women studied, 10,382 were in receipt of non-LEI AEDs
while 15,222 were in receipt of LEI AEDs. The LEI AEDs were associated with an
increased risk of fracture in people with epilepsy as compared to those with epilepsy
treated with non-LEI AEDs. The increased risk for all fracture sites, in men, with LEI as
compared with non-LEI was reflected by adjusted HR 1.09, 95% CI 0.98 – 1.2, p = 0.123
and was therefore not deemed to be significant. For women there was a slightly
greater increase in the risk of fracture at any site (adjusted HR 1.22, 95% CI 1.12 – 1.34;
p < 0.0010). When the sample was adjusted to include only those over 50 the author
stated the results did not alter, but did not include same. Regarding hip fractures,
there was a greater risk with LEI AEDs than non-LEI AEDs for men (adjusted HR 1.53;
95% CI 1.10 – 2.12, p = 0.011). There was also a greater risk with LEI AEDs than non-LEI
AEDs for women (adjusted HR 1.49; 95% CI 1.15 – 1.94, p = 0.002). The authors state
this suggested that hazard ratio for hip fracture was of a greater magnitude than that
for fracture at all sites (55).
Nurminen et al in Finland, 2013, set out to assess the gender specific risk of fracture in
a population over the age of 65 associated with opioid treatment, AED treatment and
anticholinergic treatment. They also looked at fracture risk when these treatments
were used in combination, or concomitantly with psychotropic medication. The cohort
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consisted of 1,177 people over the age of 65. Of these, 482 were male, 695 were
female, with a mean age of 73.2 years. It was noted by the authors that one in twenty
of the participants resided in institutions and that the remainder lived in the
community. This study formed part of a longitudinal population based study
performed in Lieto in South-west Finland. For this study the participants were followed
up for 6 years after baseline assessment.
The exposure of interest was medication treatment with opioids, AEDs,
anticholinergics, benzodiazepines, antidepressants and antipsychotics. The AED
exposures specifically were phenobarbital, primidone, phenytoin, ethosuximide,
clonazepam, carbamazepine and valproic acid. The exposure information was recorded
by a nurse during interview with the participants. The authors also state that
prescription forms, medication containers and medical records were also checked. The
outcome of interest in this study was fracture and information regarding fracture was
obtained from medical records using “radiologic confirmation” (56). This appears to
relate to fracture at any site as there is no specific reference to site made by the
authors. The potential confounders taken into account for the female participants
were age, poor handgrip strength, body mass index below 30kg/m2, compression
fracture in one or more upper lumbar or thoracic vertebrae. For the male participants
the confounders included were old age, multiple depressive symptoms and
compression fracture in one or more upper lumbar or thoracic vertebrae.
The results found that 11 men and 10 women used one AED and three men used two
or more AEDs. No women in the study were found to use two or more AEDs. Three
men and one woman used an AED and an antipsychotic medication. Six men and three
women used an AED and a benzodiazepine. Three men and one woman used an AED
and an antidepressant. The only reported result for men was the ‘two or more AEDs’
subgroup. At three year follow up one of the men had sustained a fracture, generating
a RR 8.2, 95% CI 1.1 – 60.8, p = 0.04. When this was adjusted for age, the RR was 6.6,
95% CI 0.9 – 49.6, p = 0.07, and was therefore not significant. The results shown for
women using one AED at 6 year follow up showed a RR of 3.5, 95% CI 1.3 – 9.7, p =
0.01. When this was adjusted for age, the RR was 3.0, 95% CI 1.1 – 8.2, p = 0.03. When
multivariate analysis was carried out the RR was 2.7, 95% CI 0.8 – 9.2, p = 0.1.
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Therefore, the association was not significant after adjustments were made for
potential confounders (56).
Velez et al in the USA, 2014, sought to examine the risk of bone fracture among
patients with epilepsy in the United States. The population in this cohort was sourced
from the PharMetrics Database. This is a longitudinal population database with drug
and diagnosis data, medical and pharmacy insurance claims and outpatient and
inpatient information. It refers to people with Medicaid, Medicare or other commercial
health insurance (59). The mean age of the patients was 47.6 years and the follow up
period was for six years. The patients were 55% female. 97,362 patients were selected
from the database with claims for epilepsy in the years preceding and immediately
following the index date and a cohort of the same size, matched for demographics,
without epilepsy, was also selected. The place of residence of the participants was not
stated by the author.
Exposure to AED was assessed during follow up period form the same database. The
names of the AEDs are not included by the author. Outcome of fracture was assessed
from the database information. Site of fracture was not specified by the authors.
Potential confounders assessed for in the study were age greater than 65, comorbid
osteoporosis, imbalance disorder and Alzheimer’s disease.
The results showed that 73% of the patients with epilepsy received an AED, compared
with 30.7% of the patients without a diagnosis of epilepsy, according to the database.
For those receiving the AED treatment, regardless of diagnosis of epilepsy, there was a
higher risk of fracture with an adjusted OR 1.29, 95% CI 1.24-1.35. The p value was not
reported. This study was presented as a poster and this may be the reason for the
smaller amount of information supplied (58).
3.4.1.2 Studies concerned with risk of falls only
Ensrud et al in the USA, 2002, assessed whether Central Nervous System (CNS) active
medications increased the risk of falls in 6,301 community dwelling older women. The
authors noted that black women were excluded from the study due to their lower rate
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of fracture. This was a cohort recruited for the Study of Osteoporotic Fractures, from
population-based listings in the US states of Maryland, Minnesota, Oregon and
Pennsylvania, USA. The cohort was followed up for an average of 4.8 years. The initial
recruitment for the Study of Osteoporotic Fractures was in 1986-1988 (9,704 women)
and baseline examination took place at this time. In 1992 the survivors from that
original cohort were invited to have a fourth examination which included a
questionnaire and 8,127 did so by 1994. These women were then contacted by
postcard or telephone every four months, for a follow up period of one year, to ask
whether they had experienced any incident falls. The average follow-up period was
356 days.
The CNS active medication that the participants were taking is the exposure in the
study. This was ascertained in interview at a clinic visit. The participants had a clinic
visit or a home visit (or a telephone interview if neither of the above were possible) to
ascertain the medication they were taking.  All containers of prescription and non-
prescription medication were reviewed by the interviewer in the face to face
interviews. The authors generated a list of four classes of CNS active medications:
benzodiazepines, antidepressants, anticonvulsants and narcotics. The indication for
prescription of the AED was not assessed. The outcome of interest was a fall, defined
as “falling all the way to the floor or ground, or falling and hitting an object like a chair
or stair”. This was ascertained by the authors by contacting the participants every 4
months by postcard or telephone to ask about falls.
Potential confounders included in the Ensrud study were age, self-reported health
status, oestrogen use, lifestyle (including activity level and smoking), previous dizziness
and falls, cognitive impairment, weight change, bone mineral density, speed when
walking and ability to rise from a chair.
Regarding AED use, 123 participants, or 2% of the cohort were active users of AEDs,
almost all of whom (95%) were daily users. 65 were taking phenytoin, 34 were taking
phenobarbital, 27 were taking carbamazepine and 12 were taking another AED which
was not specified. The authors state that 50% of those using AEDs had a diagnosis of
seizure disorder. Those using AEDs were found to be at a higher risk of falls with an
age-adjusted RR 2.49, 95% CI 1.73 – 3.58. The multi-variate RR is 1.75, 95% CI 1.13 -
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2.71. There was also at significantly increased risk of frequent falling when AEDs were
used, with an age-adjusted RR 3.15, 95% CI 2.08 – 4.77. The multivariate adjusted RR
was 2.56, 95% CI 1.49 – 4.41. The authors stated the results did not alter when seizure
disorder was controlled for (50).
Merrill et al in the USA, 2005, carried out a prospective cohort study to investigate
whether there was a link between use of the AED oxcarbazepine and falls. The cohort
chosen was a group of psychiatric inpatients in Buffalo, New York. There were 23 men
and 28 women included in the study and the mean age of participants was 59. It was
noted by the authors that the oxcarbazepine, an AED, was used as an off licence
treatment for mood disorder. The period of follow up was a total of two years. The
comparison group were the patients themselves, when not on the medication, and the
period of time on the treatment was 100 days. This was described by the author as a
“rolling cohort study”.
The exposure of interest in this study was treatment with oxcarbazepine for duration
greater than one day during the study period. Falls were the outcome of interest in this
study, and the author states they were tracked using the hospital incident reporting
system. The authors state they stratified their results by age in an attempt to control
confounders.
The results showed that there were 0.69 falls per 100 patient days (95% CI 0.54 to
0.84) in those using the AED. There were 0.38 falls per 100 patient days in the
participants when they were not using the AED (52).
Ham et al in the Netherlands, 2014, used data from the B-PROOF study (B vitamins for
the prevention of osteoporotic fractures), in which the participants were from three
Dutch cities, to investigate the association between medication usage and falls. There
were 2,407 community dwelling Dutch people included in the study, and they were
aged 65 years and older. The cohort comprised 49.1% women. The indication for the
use of the medication was not assessed.
The exposure of interest in this study was use of medication. This was ascertained
from pharmacy dispensing records obtained from the Dutch Foundation for
Pharmaceutical Statistics. This holds data from 95% of the pharmacies in the
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Netherlands. Cardiovascular, CNS, respiratory system and ‘miscellaneous’ medications
were included. Among the CNS drugs was a section for AEDs but individual, named
AEDs were not recorded. The outcome of interest was incidence of fall. A fall was
defined as an unintentional change in position resulting in coming to rest at a lower
level or on the ground (10). Fall incidents were recorded using a fall calendar, which
was returned to the team every three months. If the details provided by the
participant were unclear, the participant was contacted by a member of the team
conducting the study, for more details. Potential confounders controlled for were age,
gender, use of a walking aid, history of falls and fractures, health status variables which
included smoking status, alcohol use, cardiovascular disease, diabetes and
hypercholesterolemia.
Of the cohort, 42 (or 1.7%) were users of AEDs. The authors state there was no
significance found in the risk of falls in users of AEDs versus non-users. The hazard ratio
for the crude model showed HR 1.44; 95% CI 0.95 – 2.18. When this was adjusted for
confounders the HR was 1.31; 95% CI 0.87 – 1.98. The p value was not reported. The
wide confidence interval is notable here (57).
3.4.1.3 Studies concerned with risk of both falls and fractures
Tromp et al in the Netherlands, 1998, sought to identify easily measurable predictors
for falls and fractures. They used data from the Longitudinal Aging Study in
Amsterdam, which studied people in three regions of the Netherlands over a period of
10 years. The participants were 65 and older at the end date of the study, and the
mean age of participants was 72.6 years. The authors noted that they excluded people
living in institutions and described the participants as community dwelling. The cohort
consisted of 764 men and 705 women (total 1405). The average follow-up period was
37.8 months.
There were a number of potential risk factors assessed in this study. The exposure of
interest to this systematic review is treatment with medication, specifically AEDs. The
information regarding medication usage was obtained from review of the participants’
medication containers. The specific types of AEDs included were not recorded. The
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indication for the medication was not specified. The outcome of interest was (i) the
occurrence of falls in the year prior to the follow up examination and (ii) the
occurrence of a fracture during a 38 month follow up period. A fall was defined as an
unintentional change in position resulting in coming to rest on the ground or other
lower surface level such as a chair or stair. Regarding the second outcome, recurrent
falling was also captured. Both outcomes were captured via self-report. Confounders
allowed for in this study were age and gender. The authors stated they initially
calculated Odds Ratios without adjusting for these as they wanted to identify the sub
groups with the highest risk and were not concerned with elucidating causality.
The results showed that 15 members of the cohort used AEDs. There was an increased
risk of having one fall with an Odds Ratio of 6.2, 95% CI 2.0 – 19.7, p < 0.05. There was
also an increased risk of recurrent falls, with an odds ratio of 7.1, 95% CI 2.5 – 19.8, p <
0.05. There was also shown to be an increased risk of fractures, OR 4.7, 95% CI 1.3 –
17.2, p < 0.05. Once the figures were adjusted for age and gender the use of AEDs
continued to indicate an increased risk of recurrent falls with an OR of 4.7, 95% CI 1.4 –
15.9, p < 0.05. The authors acknowledged that only a small portion of the cohort used
AEDs (1).
Carbone et al in the USA, 2009, looked at AED use, falls, fractures and bone mineral
density in women aged 50 – 79 years. The cohort comprised 1385 AED users and 137,
282 non-users. The participants were from 40 clinical centres from the Women’s
Health Initiative, a long term national health study in the United States. The follow up
period for assessment of falls and fractures was 7.7 years. Users of corticosteroids
were excluded.
The exposure of interest was use of AEDs. This was assessed by having participants
bring the containers from their medications in the preceding two weeks to the
baseline and follow up assessments. The medication used by a participant was
classified via category. The AEDs were divided into two groups; enzyme-inducing and
non-enzyme inducing. The enzyme inducing category included carbamazepine,
mephenytoin, phenytoin and primidone. The category of non-enzyme inducers
included clonazepam, divalproex sodium (pharmacokinetically the same as sodium
valproate, used in European countries), gabapentin, lamotrigine, methsuxime and
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topiramate. The outcomes of interest were falls, fractures and bone mineral density.
Here the focus will be on the falls and fractures. Hip fractures were confirmed by
review of radiology reports. However, fractures at all sites were recorded. Information
regarding falls was collected via questionnaires. Falls in the course of sporting activity
were excluded.
Confounding variables included were age, ethnicity, BMI, smoking status, alcohol
intake, calcium and vitamin D intake, prevalent fracture at age 55 and over, history of
falls, medication use including hormonal treatment, diabetes, family history of hip
fracture, medical history including of Multiple Sclerosis and Parkinson’s Disease.
The results showed that of the 1385 AED users, 289 used carbamazepine, 470 used
clonazepam, 110 used divalproex sodium, 81 used gabapentin, five used lamotrigine,
three used mephenytoin, three used methsuximide, 370 used phenytoin, 67 used
primidone, one used topiramate, and six used valproic acid. The indication for use was
not recorded. When the data was adjusted for age and ethnicity and BMI, those using
a single AED were at increased risk for fracture as compared to non-users, HR1.60, 95%
CI 1.42 – 1.79. Those using more than one AED were at a greater risk than non-users
for fractures, HR 2.68, 95% CI 2.04 – 3.53. In fully adjusted models (adjusted for all
potential confounders) those using a single AED were at increased risk for fracture as
compared to non-users, HR 2.68; 95% CI 2.04 – 2.53. Those using more than one AED
were at a greater risk than non-users for fractures, HR 2.12, 95% CI 1.61 – 2.80. When
those using two or more AEDs were compared to those using just one AED (with the
data adjusted for age and ethnicity and BMI), it was demonstrated that those using
two or more AEDs were at greater risk of fracture; HR 1.68; 95% CI 1.25 – 2.26. In fully
adjusted models (adjusted for all potential confounders, as listed above), those using
two or more AEDs were compared to those using just one AED and were still found to
be at increased risk of fracture; HR 1.55; 95% CI 1.15 – 2.09. Those using enzyme-
inducing AEDs were found to be at increased risk of fracture compared to those using
non-enzyme inducing AEDs. The hazard ratio for non-enzyme inducing AEDs was 1.44;
95% CI 1.22 – 1.71; while the hazard ratio for enzyme-inducing AED users was found to
be 1.87; 95% CI 1.62 – 2.15 (with the data adjusted for age and ethnicity and BMI).
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Participants using both types of AEDs had a fracture risk hazard ratio of 3.02; 95% CI
1.85 – 4.93 (with the data adjusted for age and ethnicity and BMI).
With regard to falls, those using AEDs for less than two years had an increased risk of
falls as demonstrated by hazard ratio 2.15, 95% CI 2.00 – 2.31. Those using AEDs for
between 2 and 5 years had an increased risk of fracture as demonstrated by hazard
ration 2.05; 95% CI 1.80 – 2.33. Those using AEDs for more than 5 years had an
increased risk of falls also, with hazard ratio 2.16, 95% CI 1.92 – 2.44. The data here is
adjusted for age and ethnicity and BMI. When the data is adjusted for all potential
confounders included in the study, there was still an increased risk for users of AEDs
with a hazard ratio of 1.62; 95% CI 1.50 – 1.74.
There follows a table summarising the key findings of the studies:
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Table 3.1: Summary of key aspects of the studies chosen
Author,
year,
country
Cohort
size
Gender,
Age
(mean)
Cohort
diagnoses,
indication
for AED use
Population
based
sample
Exposure
medications
Follow up
period
Methods of
ascertaining
outcome
Confounders
considered
Risk
Ratio
Fractures only
Bohannon
et al, 1999,
USA
2590 All
female,
65 and
older,
(mean =
73.5)
Not
specified
Yes Phenytoin 6 years Self-repost of any
fracture at yearly
interview; in
person x 2,
telephone x 4
Age, ethnicity,
education, income,
residence, lifestyle
factors (including
alcohol and smoking),
medications, health
conditions (including
cognitive impairment
and depression)
Odds
ratio
Ensrud et
al, 2003,
USA
8127 All
female,
65 and
older,
(mean =
78)
Not
specified
Yes Various AEDs,
stated as
phenytoin,
phenobarbital,
carbamazepine
another AED
which was not
specified
4.8 years Self-report of all
non-traumatic
non-spine or hip
fracture when
contacted by
research team
every four months
by telephone or
postcard
Age, self-reported
health status,
oestrogen use, lifestyle
(including activity level
and smoking), previous
dizziness and falls,
cognitive impairment,
weight change, bone
mineral density, speed
when walking and
ability to rise from a
chair
Hazard
ratio
Mezuk et al,
2010, USA
67,387 97%
male,
50 and
older
29,029
participants
dx bipolar
affective
Yes Phenytoin,
fosphenytoin,
mephenytoin,
phenobarbital,
4.5 years Coding for
diagnoses of any
fracture, and hip
fracture in both
Age, gender, race,
region, income,
depression and alcohol
or substance misuse
Hazard
ratio
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disorder,
people with
epilepsy
excluded
carbamazepine,
primidone,
oxcarbazepine,
topiramate,
divalproex,
lamotrigine,
gabapentin,
tigabine,
levetiracetam
inpatient and
outpatient
administrative
records. Traumatic
fractures included.
Nicholas et
al, 2013, UK
63,259 49%
female,
mean
age 42.2
years
People with
active
epilepsy
Yes AED treatment
including one or
more liver
enzyme inducer
(LEI)or (ii) AED
treatment
including only
non-liver
enzyme inducing
(non-LEI) AEDs.
2.9 years Primary outcome
of interest:
diagnosis of
fracture recorded
in the GPRD.
Secondary
outcome of
interest: hip
fracture.
Alcohol use, previous
use of AEDs, previous
seizures, falls or
fractures, health
condition and
medication use
Hazard
ratio
Nurminen
et al, 2013,
Finland
1,283 59%
female,
65 and
older,
Mean
age 73.2
years
Not
specified
Yes Phenobarbital,
primidone,
phenytoin,
ethosuximide,
clonazepam,
carbamazepine
and valproic acid
6 years Any fracture, data
obtained from
medical records
using “radiologic
confirmation”
Females: age, poor
handgrip strength,
body mass index below
30kg/m2, Males:  age,
multiple depressive
symptoms All:
compression fracture
in one or more upper
lumbar or thoracic
vertebrae
Risk
ratio
Velez et al,
2014, USA
194734 55%
female,
mean
97,362
participants
had
epilepsy
Yes Exposure to AED,
names of which
not specified
6 Fracture (no
specifics re site
mentioned)
entered into
Age greater than 65,
comorbid
osteoporosis,
imbalance disorder
Odds
ratio
55
age 47.6
years
PharMetrics
database
and Alzheimer’s
disease
Falls only
Author,
year,
country
Cohort
size
Gender,
Age
(mean)
Cohort
diagnoses,
indication
for AED use
Population
based
sample
Exposure
medications
Follow up
period
Methods of
ascertaining
outcome
Confounders
considered
Risk
Ratio
Ensrud et
al, 2002,
USA
6301 All
female,
65 and
older,
mean
age 77
Not stated Yes Various AEDs,
stated as
phenytoin,
phenobarbital,
carbamazepine
another AED
which was not
specified
356 days Fall = “falling all
the way to the
floor or ground, or
falling and hitting
an object like a
chair or stair”.
Ascertained by the
authors contacting
the participants
every 4 months by
postcard or
telephone
Age, self-reported
health status,
oestrogen use, lifestyle
(including activity level
and smoking), previous
dizziness and falls,
cognitive impairment,
weight change, bone
mineral density, speed
when walking and
ability to rise from a
chair
Odds
ratio
Merrill et al,
2005, USA
51 55%
female,
mean
age = 59
Inpatients
in a
psychiatric
hospital,
treated for
mood
disorder
No Oxcarbazepine 2 years-
100 days
on
treatment
Falls, as reported
to hospital incident
reporting system
Age Absolut
e risk
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Ham et al,
2014,
Netherlands
2407 49.1%
female,
65 and
older,
Not
specified
Yes Various AEDs,
names not
specified
3 years Fall = unintentional
change in position
resulting in coming
to rest at a lower
level or the
ground. Self-
reported (fall
calendar, returned
every 3 months)
Age, gender, use of a
walking aid, history of
falls and fractures,
health status including
smoking and alcohol,
cardiovascular disease,
diabetes and
hypercholesterolemia
Hazard
ratio
Falls and fractures
Author,
year,
country
Cohort
size
Gender,
Age
(mean)
Cohort
diagnoses,
indication
for AED use
Population
based
sample
Exposure
medications
Follow up
period
Methods of
ascertaining
outcome
Confounders
considered
Risk
Ratio
Tromp et al,
1998,
Netherlands
1469 52%
female,
65 and
older,
mean
age 72.6
years
Not
specified
Yes Various AEDs,
names not
specified
4 years (i) Fall in the year
prior to the follow
up examination;
(ii) Fracture during
a 38 month follow
up period. Fall was
defined in same
way as Ham et al,
above. Both
outcomes
captured via self-
report
Age and gender Odds
ratio
Carbone et
al, 2009,
USA
138,667 All
female,
ages 50 -
79
Yes LEI AEDs
carbamazepine,
mephenytoin,
phenytoin and
primidone.
7.7 years Hip fractures
confirmed by
review of radiology
reports. Fractures
at all sites were
Age, ethnicity, BMI,
smoking and alcohol,
calcium and vitamin D
intake, prevalent
fracture at age 55+,
Hazard
ratio
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Non LEI AEDs
clonazepam,
divalproex
sodium,
valproate,
gabapentin,
lamotrigine,
methsuxime
topiramate
recorded.
Information
regarding falls was
collected via
questionnaires.
Falls in the course
of sporting activity
were excluded.
history of falls,
medication, including
hormonal treatment,
diabetes, family history
hip fracture, medical
history including of
Multiple Sclerosis and
Parkinson’s Disease
3.4.2 Methodological quality of the selected studies
Overall the quality of the studies was good. The findings following evaluation of
methodological quality are presented in table 3.2, which is followed by an explanatory
table, listing the aspects of the Newcastle Ottawa Scale for Cohort Studies, table 3.3.
Most of the studies have a large number of participants and are population based,
allowing for greater generalisability of results. The risk of selection bias, related to
both outcome and exposure, is greatly lessened by the prospective nature of the
studies chosen.
In some of the studies it was not possible to ascertain if any of the original cohort had
been lost to follow up and this raises the possibility of loss to follow up bias. The
outcomes and exposures assessed were clearly stated. However, their method of
assessment differed across the studies. While some of the outcomes were recorded
from medical records and radiography (51-56, 58) others were not (48-51). When self-
report measures are employed, it raises the risk of recall bias on the part of the
participant.
While the studies generally had very large cohorts, the numbers of those using AEDs
was much smaller in some of the studies. For example, Ensrud et al, 2003 (51) reported
on their population where 123 of 8127 participants were taking AEDs. Ham et al (57)
reported on 42 of their 1707 participants who were taking AEDs. Of the 1405
participants in Tromp et al’s study of falls and fractures, only 15 were using AEDs (48).
Regarding exposure to AEDs, this was not recorded in the same manner across the
studies. Some of the studies reported “any use” of an AED before the index date (54).
However, this does not totally reflect the duration of usage of AEDs for those with
chronic illnesses. In addition, participants’ prior exposure to other AEDs was not
always reflected as a covariate and this may affect the participants’ risk, in addition to
their treatment at the time of the assessment.
There are many potential risk factors for osteoporosis, including age, sex, race, low
bone mass, low body weight, oestrogen deficiency and previous fracture. Other risk
factors include tendency to fall, disability and immobilisation, low physical activity, use
of psychotropic/anxiolytic/hypnotic drugs, use of corticosteroid, low calcium intake in
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the elderly, osteomalacia, thyrotoxicosis, cigarette smoking, chronic alcoholism,
diabetes mellitus, and insufficient sunlight exposure (60). While many of the studies
took some or most of these potential confounders into account, they did not all take
the same confounders into account in each study.
As shown in the summary table 3.1, the studies included assessed risk using different
parameters. Some of them used odds ratios (48-50, 58). A further five studies reported
hazard ratios (51, 53-55, 57). One study reported its findings in terms of risk ratios (56)
and another reported absolute risk (52). This results in difficulty in pooling the data.
Table 3.2: Newcastle Ottawa Scale results for studies included in the systematic
review
Study (by Author) Newcastle Ottawa Scale
Selection Comp Outcome
1 2 3 4 1 1 2 3
Fractures only
Bohannon et al, 1999      0  
Ensrud et al 2003        
Mezuk et al, 2010       0 ?
Nicholas et al,    0 0  0 ?
Nurminen et al. 2013    0    
Velez et al, 2014    0    ?
Falls only
Ensrud et al, 2002    0  0  
Merrill et al, 2005 0   0   0 
Ham et al, 2014    0  0  
Falls and fractures
Tromp et al, 1998    0  0 0 
Carbone et al, 2009    0    ?
Legend: = awarded as per NOS Quality Scale, 0= no award, ? = insufficient data
As outlined in Chapter 2, studies scoring higher than 7 are deemed high quality studies
using NOS scale. Studies scoring between 4 and 6 on the scale were assessed as being
of ‘moderate quality’, and 0-3 as being of ‘poor quality’ (46). All of the studies included
were of moderate or high quality, with scores shown above.
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Table 3.3: Newcastle Ottawa Quality Scale for Cohort Studies, Ottawa University (46)
Selection 1. Representativeness of the exposed cohort
Truly representative of the average person taking AEDs in the
community
Somewhat representative of the average person taking AEDs in the
community
Selected group of users e.g. nurses, volunteers
No description of the derivation of the cohort
Selection 2. Selection of the non-exposed cohort
Drawn from the same community as the exposed cohort
Drawn from a different source
No description of the derivation of the non-exposed cohort
Selection 3. Ascertainment of exposure
Secure record (e.g. surgical records)
Structured interview
Written self-report
No description
Selection 4. Demonstration that outcome of interest was not present at
start of study
Yes
No
Comparability 1. Comparability of cohorts on the basis of the design or
analysis
Study controls for age 
Study controls for any additional factors: gender, health, race
Outcome 1. Assessment of outcome
Independent blind assessment or reference to secure records, e.g.
medical record
Record linkage (e.g. identified through ICD codes on database
records)
Self-report
No description
Outcome 2. Was follow-up long enough for outcomes to occur
Yes (5 years for fracture to occur; 1 year for falls to occur) (61)
No
Outcome 3. Adequacy of follow up of cohorts
Complete follow up - all subjects accounted for 
Subjects lost to follow up unlikely to introduce bias - small number
lost - > 15 % follow up, or description provided of those lost
(61)
Follow up rate < 85% and no description of those lost
No statement
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Note: A study can be awarded a maximum of one star for each numbered item within
the Selection and Outcome categories. A maximum of two stars can be given for
Comparability (46).
3.5 Summary
This section of the results chapter will summarise the findings of the selected studies
across the outcome of interest: fall and/or fracture.
From the studies reviewed where fracture was an outcome it is evident that there is an
increased risk of fracture with AED treatment. Bohannon et al (49), Ensrud et al (51),
Tromp et al (48) and Carbone et al (53) demonstrated an increased risk of fractures in
those receiving AEDs, after adjustment for potential confounders. In each of these the
study population was a general population cohort and the indication for the use of
medication was not specified. Nicholas et al (55) demonstrated an increased fracture
risk in those using liver enzyme inducing AEDs in a population with epilepsy. Velez et al
(58) demonstrated an increased fracture risk in those using AEDs in a population
where half of the participants had epilepsy. Mezuk et al (54) showed an increased
fracture risk in those exposed to AEDs in a population, almost half of whom who were
diagnosed with bipolar affective disorder. Nurminen et al (56) demonstrated an
increased risk of fractures with AED usage but this increase was not significant after
adjustment for confounders.
Of the five studies that assessed AED use and risk of falls, three showed a
demonstrably increased risk, after adjustment for confounders. These were Ensrud et
al (50), Carbone et al (53) and Tromp et al (48). All of the studies looked at general
populations, and had not selected a particular patient group. Ham et al (57) did not
find a significant link between AED use and risk of falls. Merrill et al (52) described
finding an increased risk of falls in psychiatry inpatients treated with an AED
oxcarbazepine. However, the risks in the exposed group and unexposed group were
not compared using bio-statistical measurements in order to clarify whether the
difference in risk was significant.
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Chapter 4: Discussion
4.1 Introduction
The aim of this systematic review was to identify relevant and appropriate studies to
answer the question “Do anti-epileptic drugs, regardless of the treatment indication,
predict an increased risk in the incidence of falls and fractures?” Because this was a
systematic review the overarching aim was to select studies and analyse and
summarise their results in a consistent fashion, in line with the MOOSE guidelines, as
referenced in Chapter 2.
The main findings, as laid out in Chapter 3, revealed that AED use is associated with an
increased risk of fractures among the population of interest, those over the age of 18
years. This risk increase was greater for those treated with LEI AEDs than non-LEI AEDs.
The risk remained increased when seizure disorder was controlled for, and the risk was
higher in older adults. Several of the papers reviewed suggested that dietary and
lifestyle advice should be offered to those treated with AEDS and that prescribing
guidelines should be updated to reflect the results in that paper (54, 55). Some of the
researchers recommended further randomised trials of AEDs looking specifically at fall
and fractures with AEDs (53). Still others suggested clinicians familiarise themselves
with the other risk factors for falls and fractures and use this information to assist in
the choice of treatment in epilepsy (48).
There was an increased risk of falls with AED use in three of five papers reviewed.
There will follow a review of the results obtained, using an ethical and legal prism to
fully explore the breadth of the implications of the study. In order to do so the current
clinical guidelines, likely to be consulted by an Irish prescriber, will be summarised
below.
63
4.2 Current guidelines: A Summary
Despite the totality of evidence as summarised above, there is still a dearth of
standardised recommendations on AED prescribing for clinicians, particularly clinicians
outside neurology. As outlined in Chapter 1, NICE guidelines exist for prescribers when
using AEDs for epilepsy in the NHS in the UK. These state that tests of bone
metabolism should be carried out every 2-5 years for adults taking LEI AEDs (62). There
is no reference to bone health in the NICE bipolar affective disorder management
guideline (63) though it recommends using a number of the same medications as the
epilepsy guideline. There are no recommendations in the guidelines from NICE
regarding bone health advice, monitoring, or indeed bone conservation or Vitamin D
treatment for those treated for mood stabilisation purposes (6).
In 2009 the Medicines Healthcare and Regulatory Agency (MHRA), an executive agency
of the Department of Health in the United Kingdom,  highlighted the effects of AEDs on
bone and advised all healthcare professionals that “long term treatment with
phenytoin, carbamazepine, primidone and sodium valproate are associated with
decreased bone mineral density, which may lead to osteopenia, osteoporosis and
increased fractures, particularly in the following at risk patients; those who are
immobilised for long periods, those who have inadequate sun exposure, those with
inadequate dietary calcium intake” (64). The MHRA’s advice was to consider
supplementing vitamin D at risk patients who receive long term treatment with
primidone, phenytoin, carbamazepine, phenobarbital and sodium valproate (64).
The Scottish Intercollegiate Guidelines Network, in their Epilepsy Management
Guideline, advise that “patients taking AEDs should receive dietary and other lifestyle
advice to minimise the risk of osteoporosis” (65). SIGN have withdrawn their last
guideline on bipolar affective disorder, therefore there are no recommendations
regarding bone health and treatment with mood stabilisers.
Furthermore, in the United States, a review of epilepsy treatment recommended that
for those 60 and over, LEI AEDs should not be started unless the patient has failed to
respond to two non-LEI AEDs previously (66).
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Following on from this studies have been done looking at the ways to improve the
prescribing of bone protection, including using computer automated reminders when
there is a patient with epilepsy is at the clinic, in order to encourage compliance with
the NICE guidelines (67).
It is clear from the above summary that the guidelines available concentrate on this
issue as it pertains to epilepsy and are not in agreement regarding action in any case.
This systematic review demonstrated that AEDs predict an increased risk of fractures,
regardless of whether the indication is epilepsy, bipolar affective disorder or another
illness.
4.3 Ethical Issues
4.3.1 Prescribing and the risk of side effects from an ethical perspective
The decision by a doctor or healthcare professional to include a treatment in a
patient’s care plan will be made following a consideration of the clinical presentation
and diagnosis, characteristics of the patient and wishes of the patient, characteristics
of the treatment itself and the resources available. The clinician’s clinical knowledge
and expertise in weighing these up will also come into play. The decision to treat an
unwell patient with a medication with side effects is inevitable as virtually all
medications have side effects, from over the counter preparations such as
paracetamol to prescription medications for heart disease and cancer. The incidence
and severity of these vary however. The studies included in the review showed that
AEDS predict an increased risk of fracture; and three of five showed an increased risk
of falls. When assessing an unwell patient, the clinician has an ethical obligation to
make the best decision they can with the resources at their disposal. Using a treatment
that might bring about harm to the patient will be decided after careful weighing up of
the known risks and potential benefits to the patient. It will be helpful to demonstrate
how this ethical obligation is discharged using the framework of the four principles of
biomedical ethics; autonomy, beneficence, non-maleficence and justice.
65
4.3.2 Autonomy, beneficence and paternalism
Autonomy and beneficence sometimes meet in the middle, and decisions are shared
equally between the clinician and the patient (68). This is the “shared decision making”
model with the expert patient that is encouraged by our public health policy (69).
However, this is not always the case. Sometimes autonomy advances and beneficence
recedes, and vice versa (68). I want to examine autonomy and paternalism as they
relate to treatment with AEDs for physical and mental illness.
John Stuart Mill wrote “The only purpose for which power can be rightfully exercised
over any member of a civilised community, against his will, is to prevent harm to
others. His own good, either physical or moral, is not a sufficient warrant. He cannot
rightfully be compelled to do or forbear because it will be better for him to do so,
because it will make him happier, because, in the opinion of others to do so would be
wise, or even right” (70). The principle of respect for autonomy from the ethics sphere
is applied in day to day clinical care when informed consent is obtained for treatment
given.
The principle of beneficence invokes “a statement of moral obligation to act for the
benefit of others” (71). It is not sufficient to refrain from harmful acts but “agents must
take positive steps to help others” (71). Doctors, using their up to date clinical
knowledge applied to a particular individual, taking into account that individuals other
medical comorbidities, risk factors and treatments, decide on a course of treatment, in
this case an AED. The clinician is acting for the benefit of the patient in alleviating
suffering. However, when the beneficent act opposes the patient’s wishes, the act is
deemed paternalistic.
Autonomy, for Beauchamp and Childress, means that a person acts “in accordance
with a self-chosen plan” and is “free from controlling interference by others and
limitations that prevent meaningful choice” (71). This definition leads us to the
requirements for autonomous choice which are information, decision making capacity,
and freedom to choose (68). The concept of autonomy is not considered an all or
nothing entity; nor must it be present in a fixed amount. It can vary with time, illness
and the decision in question. Equally paternalism can be present or absent, weak or
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strong. It may be a silent manipulator or a loud coercion (68). Applying this definition
of autonomy to the issue of treatment with AEDs, the autonomous patient requires
information about AEDs and their side effects, including fracture risk. S/he also needs
to have decision making capacity and the freedom to make a choice about the
medication.
To achieve the requirement for information, the clinician must have access to clear
transparent evidence and guidelines regarding the issue and then impart this clearly to
the patient, using language that is easy to understand. The relevance of the
information to the patient is important, i.e. if all previous studies were on people with
epilepsy then the clinician will struggle to extrapolate the evidence to someone who is
not a member of that population. The recommendations made by expert groups are
very helpful in drawing together evidence. However, as we can see from the summary
above, a clinician must not stick solely to the guidelines relating to the illness they are
treat, e.g. treatment of bipolar affective disorder.
The capacity to decide about a medication is sometimes present for a patient, but not
always. It is not an all or nothing concept and capacity can sometimes be diminished
by illness. Sometimes all of these criteria are met for an autonomous decision, and the
discussion, with written information provided, takes place in a pleasant calm
outpatient department, with a clinician with plenty of time to spend with his/her
patients. But this is not always the case.
Example A: In neurology an unwell patient having sustained a head injury develops
seizures. This patient is started on an AED in the Intensive Care Unit (ICU). At the time
of treatment initiation the patient is unconscious and does not have the capacity to
make that decision as their capacity has been eroded by their illness.
Example B: A patient admitted for treatment of a manic episode with psychotic
symptoms will often lack insight into the fact that they are unwell and need treatment
and may require treatment, against their will, under mental health legislation. In
Ireland the mechanism for same is the Mental Health Act, 2001 (72).
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The patients in these, admittedly simplified, examples have had their capacity to make
a decision about treatment eroded by physical and mental illness and will require
treatment with medication (likely an AED) for the benefit of their health by a
beneficent clinician. In very many cases this capacity is regained following a period of
treatment. In both of these scenarios the requirement for medication continues once
the initial symptoms have resolved. This is in order to prevent further seizures as in the
first example, or relapse of mood disorder and psychosis, in the second example. Some
people lack capacity to make healthcare decisions due to lack of cognitive ability for
example in learning disability and dementia and these people do not typically regain
capacity.
In the situation where the patient regains capacity, and the medication is still required,
the benefits and side effects will be explained and the patient can then make a choice
about continuing on the medication. The freedom to make this choice is the final
component in the autonomous decision. The patients in examples A and B may be
completely free to choose, or they may feel they are not. Remaining on the treatment
that got them well is likely to be the advice of their clinician in both cases and a change
to the treatment plan may lead to a delay in discharge and increased risk of relapse.
Therefore, neither patient may feel they are completely free to choose.
In the case of the patient in example B, having been a detained patient under the
Mental Health Act, s/he will be aware of a more overtly strongly paternalistic
environment. The patient, now accepting voluntary treatment, may be concerned
about future detention. This patient may feel this concern impacts his/her freedom to
make choices regarding medication. The Mental Act states in Section 23 that a
voluntary patient may be detained for a period of 24 hours. Within that time, they
must be reviewed by a consultant psychiatrist who may proceed to an admission order
under section 24 of the Act. In order to meet the criteria of an admission order the
patient must have a mental illness in the context of the act: “A state of mind of a
person which affects the person’s thinking, perceiving, emotion or judgment and
which seriously impairs the mental function of the person to the extent that he or she
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requires care or medical treatment in his or her own interest or in the interest of other
persons (68, 72).
Given that any and all of these possible variables may be in play around the time a
treatment is initiated, the careful balance between autonomy and paternalism can be
difficult to achieve. In a hospital setting there will inevitably be pressure for beds,
along with patients’ desires to return to their family and home and work. The repeat
prescriber then has a significant responsibility in assisting the patient to make, or to
continue making autonomous choices. In psychiatry in particular, with a reputation as
strong paternalists, particular care must be taken. The obligation on the repeat
prescriber will be examined in greater detail later in the discussion.
4.3.3 Non-maleficence
The principle of beneficence as outlined above is often tied closely with the principle of
non-maleficence, which itself confers an obligation to abstain from doing harm to
others (71). Since the review results detailed in chapter 3 reveal that harm (fracture
and fall) is statistically more likely to arise when treated with the AED, then surely the
clinician has caused the harm? This principle not only obligates the clinician not to
cause harm but also no to impose risks of harm on the patient. But since, as outlined
earlier, virtually all treatment has some side effect, then how can treatment go ahead?
There are a number of reasons why treatment proceeds, even in the face of serious
and not so serious side effects. Firstly, the four principles do not operate alone. WD
Ross in The Right and the Good wrote about the four principle being viewed as prima
facie obligations and not as absolute obligations. A prima facie obligation is one which
be fulfilled unless it conflicts with an equal or stronger obligation (73). Therefore, the
doctor faced with a patient with epilepsy, mood disorder or pain can prescribe a
treatment with an associated risk or risks in order to perform his/her beneficent duty
to treat.  The beneficent nature of the act of prescribing an AED to treat mental and
physical illness must be borne in mind when one considers the clinician’s obligation vis
a vis non-maleficence. That is to say, the obligation not to harm is sometimes more
stringent than the obligation to help others, an extreme example of which is the
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obligation not to kill or disable others (71). However, in cases where the harm inflicted
is minor and a major benefit is received then the benefit is seen to outweigh the harm.
The example given to illustrate this by Beauchamp and Childress is some swelling
around an injection site (harm) when the injection brought about the lifesaving
intervention required.
A helpful specification of the principle of non-maleficence is Negligence and the
Standard of Due Care. The obligation not to impose harm also includes the obligation
not to impose risks of harm, and this specification demands that the goals pursued
justify the risks that must be imposed (71). There are two types of negligence viewed
as part of this specification (i) intentionally imposing unreasonable risk and (ii)
unintentionally but carelessly imposing risks of harm. In the case of treatment with
AEDs and risk of adverse effects, the event is serious, i.e. fracture. However, the illness
being treated is serious and can be fatal, so some risk can be accepted as part of the
treatment. Here the standard of due care invokes a responsibility to be aware of the
risk and ways to minimise that risk. The clinician whose patient develops a fracture
while using an AED was not negligent if the medication was necessary, the lowest
effective dose was used, the risks were explained and monitored for, and precautions
taken regarding other modifiable risk factors. The same clinician would be negligent if
he or she did not fulfil these obligations in exposing the patient to the smallest amount
of risk in order to receive the treatment.  Remaining up to date with medical
developments and research regarding medications prescribed is an important practical
day to day component of discharging the obligation of non-maleficence.
4.3.4 Justice in healthcare and clinical research
The principle of justice in healthcare refers to fair, equitable and appropriate
treatment for people (71). The formal theory of justice, attributed by theorists to
Aristotle, is common to all theories of justice (71). This states that equals must be
treated equally and unequals treated unequally. It does not provide criteria for
establishing equality of individuals and material principles of justice are required for
same. The principles vary somewhat and come together to form a layered approach to
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the concept of justice; these are Utilitarian theories, Libertarian theories,
Communitarian theories, Egalitarian theories, Capabilities theories and Well-being
theories. The concept of a “lottery” was used by Beauchamp and Childress (71) to
explain the difficulties with reaching an understanding about justice as it pertains to
health care. Indeed, it is easy to see injustice regarding the distribution of many social
determinants. This is not equal and the individuals in society have no control over such
attributes as their gender, race or disability status. Yet all of these factors impact
access to healthcare, survival rates, and likelihood of inclusion in research (74, 75).
Healthcare resources are finite and difficult decisions must be made about distribution
of these. The theories named above are a guide for how the principle of justice might
be applied to healthcare when resources are scarce. But the principle of justice must
also apply to research and research participation and application of the fruits of
research. Regulation in healthcare research has evolved over time, from the earliest
medical code in Prussia in 1900 which required the consent of the patient before
involvement in research. This did not stop the widespread doctor’s experimentation
that occurred in Nazi Germany during the 1940s (76) . This lead to the development of
the Nuremburg code in 1947which again aimed to ensure openness and consent
procedures (76). Regarding justice, the Nuremburg Code required that “the
experiment should yield fruitful results, for the good of society, unprocurable by other
methods” (76) perhaps reflecting a somewhat Utilitarian approach to the principle of
justice, the greatest good for the greatest number. However, the problem of unethical
research persisted and in the United States in 1974 the National Research Act was
passed. This allowed for the setting up of a commission into research on humans and
they published a report in 1979, the Belmont Report (77). Whilst there is ample
discussion about beneficence and the respect for persons, the principle of justice as
applied to research was discussed explicitly. The authors expressed concerns about the
over-representation of minority groups in research studies due to their “easy
availability, their compromised position, or their manipulability, rather than for
reasons directly related to the problem being studied” (77). They also stated that
benefits, knowledge, treatment or devices developed following research supported by
public funds should “not provide advantages only to those who can afford them and
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that such research should not unduly involve persons from groups unlikely to be
among the beneficiaries of subsequent applications of the research” (77).
There was a change in how justice as it pertains to research was viewed in the 1990s
with concerns that those in need might not be able to access clinical trials and the
potential benefits of same. The backdrop to this was the emerging Human
Immunodeficiency Virus (HIV) and Acquired Immuno-Deficiency Syndrome (AIDS). The
focus, after Nuremburg and the Belmont Report had been to protect people from the
risks from research whereas in the 1990s ensuring equitable access to research and
the results of research became as important (71).
With an eye to the systematic review completed in this thesis it is clear that much
research regarding the risks associated with AEDs has been completed. The vast
majority of the earlier research was based solely on those with epilepsy, and published
in neurology literature (78-84). Notwithstanding this, there have been some studies on
population groups and those with mental illness (85, 86) published in psychiatry and
general medical journals, broadening the awareness of the issue. As it stands, the
benefit of the detected increased risk of fractures with AEDs appears to be diverted
towards the population attending the neurology clinics with clinicians there availing of
a broad literature base, prescribing guidelines (62, 67), and now developing strategies
to better adhere to these guidelines (67).
4.4 Legal issues
4.4.1 Practising medicine and prescribing from a legal perspective
Doctors have an ethical obligation to manage his/her ongoing education and remain
aware of up to date research in order to discharge the duty of beneficence and non-
maleficence with regard to knowledge of important risk factors. The doctor also has an
ethical obligation to share the information regarding illness and treatment
appropriately and be aware of patient factors such as capacity and coercion or
perceived coercion. These are in order to discharge his/her ethical obligation regarding
patient autonomy with respect to the patient’s decision to proceed with treatment.
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The doctor must be aware of research, sometimes from outside his/her own field, in
order that their patients using AEDs have equitable access to the information available,
pending inclusion of the information in all clinical guidelines. The legal considerations
that will be examined, arising from this systematic review, in many ways reflect ways
of protecting the ethical principles espoused in the previous section.
There is a hierarchical framework that governs legal issues as they arise in medicine.
Irish Law comes from a number of sources; Bunreacht na hÉireann (the Irish
Constitution), European Law, previous legislation and previous case law. Case law
comes from decisions made by judges in the past which created precedents which are
followed in court when a similar issue arises. Arising from these structures are
additional mechanisms through which individual medico-legal concerns can be aired.
These are via the European Court of Human Rights and the medical practitioner’s
regulatory body, the Irish Medical Council. Under Bunreacht na hÉireann there are
express rights relevant to healthcare including the right to life, right to religious
freedom and right to liberty (87). There are also implied rights to bodily integrity,
privacy, dignity, autonomy and assisted decision making (87).
Sometimes patients develop complications from treatment. In the event that the
individual believes their doctor was at fault, there are a number of options for
recourse they may seek: a complaint to the doctor’s regulatory body, or a civil action in
a court of law. These are described below.
The Medical Council has power to regulate the performance of the medical profession
under the Medical Practitioner’s Act 2007 (88). Other professions have their own
regulatory bodies and corresponding legislation, e.g. Nurses and Midwives Act 2011,
Pharmacy Act 2007. An individual may make a complaint to the Medical Council
regarding a doctor. If the initial complaint is upheld, a fitness to practice hearing will be
held. The Medical Council has the power to revoke the doctor’s licence to practice, or
impose other sanctions, if the doctor was found to be at fault. There is no civil finding,
i.e. there is no compensation, and there is no criminal finding. The Medical Council will
examine the conduct of the doctor and whether he/she met the standards of ethical
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conduct and behaviour, as laid out in their Guide to Professional Conduct and Ethics
for Registered Medical Practitioners (89).
Under tort law, which is informed by common law and legislation (Medical
Practitioner’s Act), an individual may make a complaint of medical negligence about
their doctor. Tort law attempts to balance the interests of the plaintiff’s safety/right to
bodily integrity vs. the defendant’s freedom of action (90). This will be judged
following the rules and precedent created by previous case law. The court will be
interested in aspects of the clinical interaction including diagnosis, treatment and
consent to treatment (90).
In Ireland there is no specific criminal law covering the act of medical negligence. This
became topical when the case of Dr Michael Neary was in the public domain. Dr Neary
was an obstetrician who was found to have carried out unnecessary hysterectomies on
a large number of women and was struck off by the Medical Council in 2003. The
Health Service arranged for a redress scheme to allow for compensation for the
victims. Some of the women made complaints to the Gardaí but the Director of Public
Prosecutions made the decision that there was insufficient evidence with which to
proceed (91).
4.4.2 Duty of care by the prescriber
The prescriber of an AED, as with any medication, must comply with Medical Council
regulations. These include guidelines relating to consent in order that patient
autonomy in decision making be maintained. These enumerate the respect for patient
choice, describe capacity to consent and explain provision of information for patients
about the decision.  The timing of, and responsibility for, the consent process is laid
out clearly (89). The origins, in legal terms, of these regulatory guidelines will be traced
in the next section.
Maintaining competence throughout a professional career is one of the requirements
of the Medical Council. It means an onus on the doctor to update their knowledge and
skill and to recognise the limitation of the knowledge and skill that they have. This
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pertains to the prescription of medications found to have side effects, amongst other
areas of practice. Perhaps the Scottish court put it most succinctly in its decision in the
case of Hunter v Hanley, stating that it was indefensible for a doctor to say “that is
what I learnt at university and I shall go on doing it”(90).
The Medical Council lay out specific guidance regarding prescription of medication
which includes the need to “keep up to date with developments in medication safety”,
and states that doctors should “seek independent evidence-based sources of
information on the benefits and risks associated with the medication”(89).
4.4.3 Informed consent for treatment
As stated above, the requirement for informed consent for treatment is the legal
mirroring of the right to autonomy. Doctors have a duty under common law to obtain
informed consent. While this might seem obvious the precedent for same is set by
previous cases. A classic judgement from a case, now over 100 years old, from New
York reads “Every human being of adult years and sound mind has a right to determine
what should be done with his body; and a surgeon who performs an operation without
his patient’s consent commits an assault for which he is liable in damages"(92). The
concept of consent was reviewed and examined in further court hearings over the last
100 years. These decisions and recommendations gave rise to the development of
principles that guide doctors when they are communicating with a patient about a
treatment or intervention (89). The patient must understand and appreciate the
ramifications of a consent. If all necessary facts have not been made known in simple
terms, with assistant pamphlets or information aids, then the consent is not an
informed one.
An aspect of the informed consent process very pertinent to the systematic review
conducted in this thesis is the information, the necessary facts, given to the patient
about the risks associated with a particular treatment. The Medical Council states:
“You must give patients enough information, in a way that they can understand, to
enable them to exercise their right to make informed decisions about their care.
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Consent is not valid if the patient has not been given enough information to make a
decision”(89). The guideline goes on to recommend how to do this but acknowledges
that the amount of information required will vary from patient to patient, depending
on the nature of the condition, the type of treatment or intervention, the risks
attendant on treatment and non-treatment and the patient’s wishes (89). The
guideline notes that a patient’s beliefs, occupation and culture will also impact on their
requirement for information and recommends checking to see if the information
provided was understood (89). This is a summary of the recommendations regarding
information to be given. These most up to date guidelines, published in 2016, and
distributed in hard copy to every registered medical practitioner in Ireland, emphasize
the importance of information sharing regarding treatment and intervention. This
underscores previous rulings by the courts regarding medical negligence claims that
hinged on the information sharing facet of the consent process.
In court rulings there have been three approaches to the disclosure of information: the
first is the professional standards approach and the second is known as “the
reasonable patient” approach, and lastly a middle ground between the two (90). The
professional standards approach means that a doctor must give the patient the
information that another doctor, also a specialist in their field, would give to a patient.
The reasonable patient standard refers to giving all information, risks, and alternative
options that a reasonable person in the patient's situation would consider important,
in deciding to have, or not have, the proposed treatment.  In the case of Walsh v The
Family Planning Services, 1984, the members of the court disagreed as to which of the
rules to apply. The members of the court felt the fact that adverse effects in the case
were serious and had arisen from an elective, as opposed to a medically vital,
procedure was important (90). In this case the professionals called said they would not
have told the patient about the very tiny risk of the adverse effect (orchidalgia) either
and the Chief Justice was happy with this (90). While the case did not hinge on this
matter the disagreement left things somewhat unclear, but there did come a
recognition of the different threshold required for disclosure of risks in elective versus
medically essential treatment.
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The case of Geoghegan v Harris (2001) raised this issue, again with an elective
procedure. While judgments in the intervening period had come down on both side of
the argument, in this case the court ruled that in the patient had the right to know all
material risks (90).
While there is no criminal charge of medical negligence, an examination or
intervention where informed consent is not given it could be viewed as an assault,
which is a criminal charge. In summary, a doctor who does not obtained informed
consent in the appropriate manner laid out in the regulatory guidelines could face civil
proceedings under tort law, criminal proceedings if an assault charge is brought, and
regulation by the Medical Council for breach of its code of ethics and conduct.
4.4.5 Regulatory guidelines for repeat prescribers
Much of the emphasis around ethical and legal duties regarding treatment so far has
been focussed on what ought to happen prior to and at the time treatment is initiated.
However as alluded to in the Medical Council guidelines, doctors need to keep up to
date with developments regarding medication on an ongoing basis (89). While this is
relevant to choosing a preparation it should also be read as pertaining to new
developments with regard to medications that have already been started. When a
medication is started in a specialist clinic, such as a psychiatry or neurology clinic, there
is usually, if not always, senior medical team involvement. The follow up care may
involve a return to the clinic where the patient may see any member of the team. Or
they may be followed up by their general practitioner. For example, it has been shown
that approximately 60% of medications for psychiatric illness are prescribed by general
practitioners (93).
The General Medical Council is the Regulatory body for doctors in the UK. As with the
Irish Medical Council, they give advice regarding professional conduct and ethics for
doctors. In addition to general prescribing advice they also give specific
recommendations regarding repeat prescriptions and the repeat prescriber, stating
“You are responsible for any prescription you sign, including repeat prescriptions for
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medicines initiated by colleagues, so you must make sure that any repeat prescription
you sign is safe and appropriate. You should consider the benefits of prescribing with
repeats to reduce the need for repeat prescribing” (94). Furthermore, there is the
following recommendation: “When you issue repeat prescriptions or prescribe with
repeats, you should make sure that procedures are in place to monitor whether the
medicine is still safe and necessary for the patient”(94).
This facet regarding whether the medication is ‘still safe’ is relevant to the emergence
of new research about side effects or the patient’s changing condition, e.g. developing
other risk factors for developing a condition. The Medical Protection Society (MPS) are
the medicolegal organisation through which healthcare professionals in Ireland and
elsewhere obtain professional indemnity cover. Their advice sheet regarding
prescribing makes this very clear; stating “responsibility is the same whether it is a first
or repeat prescription. It is important to be aware that the person who signs the
prescription will be held accountable should something go wrong” (95).
4.5 Strengths and weaknesses of the systematic review
This systematic review benefitted from its summarising the totality of evidence from a
wide range of countries and populations. The cohort sizes were large and all but one of
the studies was population based. A population based study benefits from greater
generalisability of the results to the population at large. The populations studied
included both men and women. Another strength of this systematic review was that
the findings were consistent across the studies included in the review. This can be seen
from the summary of the results of the included studies in chapter 3. Robust methods
were used to screen the initial search results, and then identify and select titles. The
methodological appraisal employed to assess methodological quality used validated
criteria, the background to which was explained in Chapter 2. There were strengths
evident in the assessment of outcomes of interest. The assessment of the outcome of
fracture was by coding for diagnoses in hospital medical records. There were some
studies where fractures were verified by radiographs. Both of these methods were
found to be of high methodological quality by the Newcastle Ottawa Scale. Regarding
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falls, Ensrud et al (50) contacted participants by postcard or telephone every four
months, for a follow up period of one year, to ask whether they had experienced any
incident falls. The average follow-up period was 356 days. This is keeping with best
practice for assessment of falls in research, as assessed by the PROFANE group
following systematic review (44).
There were a number of limitations experienced in conducting this study. The studies
included were conducted in a number of countries; there were seven in the United
States, two in the Netherlands, and one each in the UK and Finland. There were no
high quality studies from countries with lower incomes. This is of concern as the WHO
reports that 2.4 million people are diagnosed with epilepsy each year, but the burden
of epilepsy in greater in poorer countries (6). “In high-income countries, annual new
cases are between 30 and 50 per 100 000 people in the general population. In low- and
middle-income countries, this figure can be up to two times higher” (6). Possible
reasons for same include increased risk of endemic conditions such as malaria; the
higher incidence of road traffic injuries; birth-related injuries; and variations in medical
infrastructure, availability of preventative health programmes and accessible care (6).
The WHO estimate that close to 80% of people with epilepsy live in low- and middle-
income countries (6).
Some of the population based cohort studies were based on primary data, that is, data
collected for this specific study, such as the studies by Bohannon and et al and Ensrud
et al (49, 51). Others, used secondary data from administrative databases to calculate
the incidence of exposure and outcomes reported, an example of which was the Velez
et al study (58) using the PharMetrics Database. When the study uses primary data
there is greater ability to manage confounding variables and obtain greater detail
about outcomes and exposures. However, many studies of longer duration (of follow
up) use secondary data, such as that from databases, due to greater ease and lower
cost of data collection.
Another limitation in this review was the heterogeneity evident with regards to how
the exposure and outcome measures were determined. The exposure of interest in
this study was the use of AEDs and the methods to ascertain same differed. Some of
79
the studies used in person interviews where the containers of medications used in the
preceding two weeks were assessed by a trained interviewer. Others relied on the
evidence from an administrative database that the medication was prescribed. Studies
have shown that there is a compliance rate of approximately 50% with medication
treatment for long-term illness (96). Therefore, accepting the exposure assessment
from a prescription or General Practice database may not give a fully accurate account
of the actual rates of AED use. While the use of in-person interviews to assess an
exposure rate more highly than database findings there remains the likelihood that not
all of the exposures were true exposures for the full period of follow up. That is to say,
it brings the assessor to the point of dispensing of the medication with certainty but
does not provide the same certainty with regard to regular ingestion. Serum levels of
medication, while likely to give a very accurate reading of exposure, are not
appropriate to these kinds of studies for ethical and cost reasons. Therefore, the most
accurate, while still remaining pragmatic, approach to assessing this kind of exposure is
an in-person interview. Regarding outcomes of interest there was also evidence of
heterogeneity in the assessment of same. Some of the methods of assessment were of
high quality as outlined above, however this was not consistent across all of the
studies. For example, some of the studies reporting on fractures used self-report data
and some of the studies on falls used hospital incident report data.
4.6 Areas for further research
Arising from the information found in this systematic review and ethical and legal
discussion there are a number of areas where future research is indicated. Carbone et
al in 2010 recommended randomised trials of AEDs looking particularly at falls and
fractures (53). This is particularly relevant given the different findings for LEI AEDs
versus non-LEI AEDs in the studies in the systematic review. Looking at the issue from a
psychiatry standpoint, randomised trials of the AEDs used in bipolar affective disorder
specifically with comparisons to atypical antipsychotic treatments from the
perspective of physical health side effects may provide a more definitive answer for
psychiatrists.
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Randomised trials of bone protecting medicines in those using AEDs for both physical
and mental illness would be the best way to assess whether making a
recommendation for treatment with same is the best way to proceed. The increased
risk of fracture is present in all groups using the medications and the
recommendations around managing this risk should, if possible, be based on high
quality evidence based on studies in all groups.
Another possibility for study is a trial of assessment of specific markers, such as
vitamin D levels or bone density in those with mental illness and use of AEDs. This
would be useful given the fact that some of the patients may have many more other
risk factors for development of osteoporosis and osteoporotic fractures. Assessment of
a particular marker may allow for selected treatment.
Mezuk et al and Nicholas et al advocated for the provision of dietary and lifestyle
advice to those taking AEDs (54, 55). Observation of the impact of same on the
outcome of fractures would best inform clinicians and allow for generation of a
business case for service providers regarding provision of appropriate resources and
personnel.
The above types of studies would allow for generation of more precise
recommendations and definitions of terms used in the existing MHRA
recommendations such as “long-term” and “high-risk” as they pertain to people using
AEDs with comorbid mental illness.
The absence of poorer countries from the studies included was a reflection of the
greater data generated by the initial search string (Appendix 1 and Flow Chart 3.1).
Therefore, assessment of this important clinical issue as it pertains to those outside
the United States and Western Europe is necessary so the management and treatment
advice used by clinicians everywhere is appropriate to the population being treated.
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4.7 Summary
Viewing the prescription of AED treatment (with risks of side effects) through an
ethical and legal prism shows that constant attention to the four principles of bioethics
is required, long after the initial treatment decision is made and initial prescription
written. This process is structured and aided by regulatory and legal percept which
have been developed over years of interaction between the legal system and complex
healthcare matters. This is essential so that people are aware of the risks attendant on
their treatment. Patients can then best make a decision that suits their needs and
wishes.
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Chapter 5 - Conclusion
5.1 Implications for policy makers
There have been no local policies in use in mental health care settings in Ireland, of
which I am aware, regarding AED use and the management of risks of falls and
fractures. Texts such as the Maudsley Prescribing Guidelines do not at present contain
advice regarding management of bone health when prescribing mood stabilising AEDs
(97). Given that this is a source often consulted by psychiatrists prior to beginning a
treatment or indeed writing a repeat prescription, it would be highly beneficial to see
the most up to date evidence there reflected. The policies used by the NHS have been
discussed in the previous chapter. There is an urgent need to update the mental health
arm of guidelines such as the NICE guidelines to reflect the risk as it pertains to all
users of AEDs. The recommendations for future research, as discussed in the previous
chapter, will help to inform policy makers about appropriate guidelines for monitoring
and treatment of adverse effects encountered in relation to AEDs.
5.2 Other recommendations
Given that people with mental illness have poorer physical health that those without
(as discussed in chapter 1) the importance of liaison between specialist mental health
services and primary care services is vital. The shared management of a complex issue,
like the one examined here, is best managed by close follow up with both general
practitioner and psychiatry/neurology, as appropriate. Sharing of patient information
is one of the best ways to do this. However other information must also be shared
among medical colleagues regarding up to date information from conferences,
lectures, research and Continued Professional Development activities.
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5.3 Systematic review
This systematic review with its comprehensive and transparent search strategy
allowed the author to identify the appropriate studies to be included. Standardised
reporting guidelines were followed. As outlined in Chapter 4 further study is needed to
more fully elucidate the problem, and reveal possible solutions.
5.4 Final comments
The importance of ongoing, appropriately shared research is evident from the study
presented here. In order that medical practice and medical research continue to
progress and develop the safeguards on research and practice in the form of
regulation must be maintained, while simultaneously encouraging future research.
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Appendix 1- Search String
Search Strategy for NCBI (PubMed) from 1967 to June 2016
#1 “Anticonvulsants” [MeSH]
#2 “Carbamazepine” [MeSH]
#3 “Phenobarbital” [MeSH]
#4 “Lamotrigine” [MeSH]
#5 “Gabapentin” [MeSH]
#6 “Topiramate” [MeSH]
#7 “Valproic acid” [MeSH]
#8 “Etiracetam” [MeSH]
#9 (OR #1-8)
#10 (anticonvulsant* OR anticonvulsive agent* OR antiepileptic drug* OR
Carbamazepine* OR Phenobarbital* OR Lamotrigine* OR Gabapentine* OR Topiramate*
OR Valproic acid* OR Etiracetam*)
#11 (#9 OR #10)
#12 “Fractures, Bone” [Mesh]
#13 (fracture* OR bone* broken)
#14 (#12 OR #13)
#15 “Osteoporosis” [Mesh]
#16 (osteoporosis OR osteopenia)
#17 (#15 OR #16)
#18 “Bone Density” [Mesh]
#19 (bone density OR bone loss OR bone mass)
#20 (#18 OR #19)
#21 (fall*)
#22 (#11 AND #14)
#23 (#11 AND #17)
#24 (#11 AND #20)
#25(#11 AND #21)
#26 (#22 OR #23 OR #24 OR #25)
#27 Humans/lim
Search Strategy for EMBASE from 1967 to June 2016
#1 Anticonvulsants/exp
#2 Carbamazepine/ exp
#3 Phenobarbital/ exp
#4 Lamotrigine/ exp
#5 Gabapentine/ exp
#6 Topiramate/ exp
#7 Valproic acid/ exp
#8 Etiracetam/ exp
#9 (OR #1-8)
#10 (anticonvulsant* OR anticonvulsive agent* OR antiepileptic drug* OR
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Carbamazepine* OR Phenobarbital* OR Lamotrigine* OR Gabapentine* OR Topiramate*
OR Valproic acid* OR Etiracetam*)
#11 (#9 OR #10)
#12 Fractures/exp
#13 (fracture* OR bone* broken)
#14 (#12 OR #13)
#15 Osteoporosis/exp
#16 (osteoporosis OR osteopenia)
#17 (#15 OR #16)
#18 Bone Density/
#19 (bone density OR bone loss OR bone mass)
#20 (#18 OR #19)
#21 (fall).tw
#22 (#11 AND #14)
#23 (#11 AND #17)
#24 (#11 AND #20)
#25(#11 AND #21)
#26 (#22 OR #23 OR #24 OR #25)
#27 humans/lim
Search Strategy for ISI Web of Science from 1967 to June 2016
#1 (anticonvulsant* OR anticonvulsive agent* OR antiepileptic drug* OR
Carbamazepine* OR Phenobarbital* OR Lamotrigine* OR Gabapentine* OR Topiramate*
OR Valproic acid* OR Etiracetam*)/
#2 (fracture* OR bone fracture* OR bone* broken)/
#3 (osteoporosis OR osteopenia)/
#4 (bone density OR bone loss OR bone mass)/
#5 (fall*)/
#6 (#1 AND #2)
#7 (#1 AND #3)
#8 (#1 AND #4)
#9 (#1 AND #5)
#10 (#6 OR #7 OR #8 OR #9)
Search Strategy for Cochrane Library from 1967 to June 2016
#1 “Anticonvulsants” [MeSH]
#2 “Carbamazepine” [MeSH]
#3 “Phenobarbital” [MeSH]
#4 “Lamotrigine” [MeSH]
#5 “Gabapentine” [MeSH]
#6 “Topiramate” [MeSH]
#7 “Valproic acid” [MeSH]
#8 “Etiracetam” [MeSH]
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#9 (OR #1-8)
#10 (anticonvulsant* OR anticonvulsive agent* OR antiepileptic drug* OR
Carbamazepine* OR Phenobarbital* OR Lamotrigine* OR Gabapentine* OR Topiramate*
OR Valproic acid* OR Etiracetam*)
#11 (#9 OR #10)
#12 “Fractures, Bone” [Mesh]
#13 (fracture* OR bone* broken)
#14 (#12 OR #13)
#15 “Osteoporosis” [Mesh]
#16 (osteoporosis OR osteopenia)
#17 (#15 OR #16)
#18 “Bone Density” [Mesh]
#19 (bone density OR bone loss OR bone mass)
#20 (#18 OR #19)
#21 (fall*)
#22 (#11 AND #14)
#23 (#11 AND #17)
#24 (#11 AND #20)
#25(#11 AND #21)
#26 (#22 OR #23 OR #24 OR #25)
Search Strategy for PsychInfo from 1967 to June 2016
#1 “Anticonvulsants” [MeSH]
#2 “Carbamazepine” [MeSH]
#3 “Phenobarbital” [MeSH]
#4 “Lamotrigine” [MeSH]
#5 “Gabapentine” [MeSH]
#6 “Topiramate” [MeSH]
#7 “Valproic acid” [MeSH]
#8 “Etiracetam” [MeSH]
#9 (OR #1-8)
#10 (anticonvulsant* OR anticonvulsive agent* OR antiepileptic drug* OR
Carbamazepine* OR Phenobarbital* OR Lamotrigine* OR Gabapentine* OR Topiramate*
OR Valproic acid* OR Etiracetam*)
#11 (#9 OR #10)
#12 “Fractures, Bone” [Mesh]
#13 (fracture* OR bone* broken)
#14 (#12 OR #13)
#15 “Osteoporosis” [Mesh]
#16 (osteoporosis OR osteopenia)
#17 (#15 OR #16)
#18 “Bone Density” [Mesh]
#19 (bone density OR bone loss OR bone mass)
#20 (#18 OR #19)
#21 (fall*)
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#22 (#11 AND #14)
#23 (#11 AND #17)
#24 (#11 AND #20)
#25(#11 AND #21)
#26 (#22 OR #23 OR #24 OR #25)
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Data Extraction tool
Title:
Author:
Year:
Country of research team:
Study design:
Population:
Age:
Gender ratio:
Race/ethnicity:
Follow up year:
Outcome definition:
Exposure definition:
Effect estimates with 95% Cis and variables adjusted for:
